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Chemogenomics Knowledgebase And Targethunter For 
Polypharmacology Analysis Of A Traditional Chinese Herbal Formula, "Sini Decoction" 
 Shifan Ma, M.S.  
University of Pittsburgh, 2015 
To enhance therapeutic efficacy and reduce adverse effects, practitioners of traditional 
Chinese medicine (TCM) often prescribe a combination of multiple herbs, called Traditional 
Chinese Herbal formulae (TCHF), according to the compatibility principle of TCM. To clarify 
the possible compatibility mechanism of formulae with systems polypharmacology analyses, we 
use Sini Decoction (SNT), which has been proven to be effective in treating cardiovascular 
diseases (CVD), as a model. The main components of SND are Aconitum carmichaeli Debeaux 
[Ranunculaceae], Zingiber officinale Roscoe [Zingiberaceae] and Glycyrrhiza uralensis Fisch. ex 
DC [Febaceae]. In this research, we initially construct a chemical library with 347 reported 
constituents in SND, and narrowed the library to 40 compounds by selecting representative 
chemical structures. Then,  we constructed several databases for the specific indications of SND, 
including heart failure, myocardial infarction, and shock, and an integrated database for CVD to 
perform high throughput docking with the 40 compounds in SND. Systems pharmacology is 
applied to investigate the polypharmacological mechanisms of SND formulae in treatment of 
Xiangqun Xie 
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CVD. The predicted results showed that 31 ingredients in SND were associated with 33 targets 
related to the autonomic nervous system, the renin-angiotensin aldosterone system, blood 
coagulation, ionic channels and the glucocorticoid receptor. Through analysis of the compound-
target interaction, we found multiple active chemical ingredients might interact with the same 
target, thus explaining the synergistic mechanisms of SND as ‘‘Jun (emperor) - Chen (minister) - 
Zuo (adjuvant) - Shi (courier)’’. To validate the polypharmacological effects predicted by 
molecular docking, the experimental validation was further performed on three selected 
representative constituents (aconitine, liquiritin, and 6-gingerol) according to our predicted 
results. The results showed that the three constituents combination could produce the same 
cardiac effects in the rat heart failure model with the combination of three herbs in SND, and 
confirmed the three constituents we predicted are most likely the active constituents. This 
computational systems pharmacology data revealed that aconitine was the principal component 
of the formula, whereas liquiritin and 6-gingerol served as adjuvant ingredients, as 6-gingerol 
can enhance the cardiac effects of aconitine, and liquiritin can alleviate the arrhythmia caused by 
aconitine. The predictions are all congruent with the other reports and experiments results. 
Key words: Synergistic Effect; Chinese Medicinal Formula; Sini Decoction; 
Polypharmacological Analysis 
Xiangqun Xie 
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1.0  INTRODUCTION 
 
1.1 SINI DECOCTION 
 
 Sini decoction (SND) is a traditional Chinese herbal formula consisting of three different 
herbs: Aconitum Carmichaelii Debeaux [Ranumculaceae] (AC), Zingiber Officinale Roscoe 
[Zingiberaceae](ZO), and Glycyrrhiza Uralensis Fisch. ex DC. [Fabaceae] (GU). SND is 
officially recorded in the Chinese pharmacopoeia 2010 edition and has been used to treat 
cardiovascular diseases for many years. AC is the principal herb in SND, and it plays the main 
pharmacological actions of this formula. ZO is the assistant and complement herb, and GU is the 
herb that reduces the toxicity induced by AC, and guides AC and ZO to their target tissues [1].  
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Figure 1. Synergistic Effect of Sini Decoction for Cardiovascular Diseases 
The three herbs in Sini Decoction have limited therapeutic effect or have some toxic effect when 
used alone. However, if used in combination, they will have improved therapeutic effect with 
reduced toxicity. 
Traditional Chinese medicine (TCM) often holistically restores the balance of Yin-Yang 
in the body energy, thus reviving the body’s normal function and homeostasis. Herein, SND, a 
well-known life rescue medication, is recorded in the Treatise on Febrile Diseases and other 
ancient Chinese medical textbooks to improve Yang deficiency, thus restoring the balance of 
Yin-Yang to treat different types of cardiovascular and other diseases, such as myocardial 
infarction (MI) [2], congestive shock, liver failure [3], hyperlipidemia [4], diabetes [5], and heart 
failure (HF) [1]. Although the single herbal medicine AC can treat cardiovascular diseases, it 
will cause cardiac toxicity but it can be made safer and the therapeutic effect enhanced by 
combination with the two herbal medicines of ZO and GU [6]. On the hand, ZO and GU have 
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less efficacy comparing with AC when used alone to treat CVD. Accumulated evidence has 
proved that SND can treat cardiovascular diseases with decreased toxicity and increased efficacy 
in combination with ZO and GU especially heart failure and myocardial infarction. Some 
previous studies focused on the pharmacokinetic profile of Sini Decoction, to study the 
synergistic effects among the three herbs on rat models [2, 7-9].  
It is common knowledge that a multi-herbal formula exerts therapeutic efficacy through 
synergistic effect of its multiple ingredients that attack multiple targets in multiple channels. 
Though many compounds have been isolated and identified in Sini Decoction [10], revealing the 
holistic mechanism of the pharmacological action of SND remains a difficult task due to the 
unknown active compounds and the unknown synergistic actions that take place in SND. 
Additionally, it is time-consuming, costly, and tedious to use the traditional methods for active 
components screening, potential targets identification, and TCM formulae mechanism 
understanding [11].  
Recently, the combined use of computational screening and polypharmacology analysis 
is emerging as a promising way to identify the potential drug targets in TCM and to clarify the 
pharmacological mechanisms of the formula [7, 12]. As a system biology-based methodology, 
system pharmacology offers an effective approach to evaluate TCMs’ polypharmacological 
effects at the molecular level for exploring the complex interactions of small molecules and 
proteins in a biological system. Therefore, in our research, systems polypharmacology is 
employed to screen the active components from the medical herbs. We then verified the targets 
predicted and pharmacological actions in the rat models we built. 
Previous studies by our collaborators have identified 51 chemical ingredients in SND [10, 
13-16]. The results provided a material basis for further polypharmacology analysis. In the 
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present study, we applied our established in silico docking approach to predict potential targets 
of the SND active ingredients. Firstly, we constructed a biological network of the interactions 
between the chemical compounds and target proteins at the molecular or systematic level based 
on our prediction. Then we investigated the effects of selective components in SND. Finally, we 
validated the predicted targets on the rat models of myocardial infarction and heart failure caused 
by coronary artery ligation. The combined approaches offer a deeper understanding of the 
pharmacological mechanisms of SND, and may provide a novel and efficient way to dissect the 
compatibility mechanism of TCMs. 
 
 
1.2 SYNERGISTIC EFFECT OF INGREDIENTS IN TCM 
 
To get efficacy-enhancing and toxicity-reducing effects of TCM, formulas containing 
several medicinal herbs are usually required based on clinical treatment experience in China. For 
complicated or multi-factorial diseases, accumulating evidence indicates that TCM can usually 
achieve a better therapeutic efficacy using multiple drugs with common and different 
pharmacological targets instead of one drug-one target [17]. TCM is an empirical healthcare 
system under the guidance of the TCM theory based on several millennia of treatment. Typically, 
the medicinal herbs in a formula can be classified into principal (Jun), assistant (Chen), 
complement (Zuo), and guide (Shi) components according to their roles in the prescription, in 
which the principal herb performs the main pharmacological actions, and the others perform 
synergistic actions to yield maximal therapeutic efficacy with minimal adverse effects [17, 18]. 
According to the polypharmacological theory, these essential multi-components play multiple 
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pharmacological roles by reacting with different but related targets: this is also known as the 
compatibility mechanism [19-21]. Network polypharmacology is used to unravel synergistic 
mechanism of drug combinations in TCM [20].  
It is possible that the multiple compounds in the SND formula could interact with 
multiple targets and act synergistically to heal illnesses. However, it is a time-consuming, costly 
and challenging task to identify the essential potential target and understand the systematic 
mechanism for the TCM formulae experimentally. Thus in this study, we applied computational 
network pharmacological approaches and high throughout virtual screening to investigate the 
potential target for the synergistic effect of SND ingredients at the molecular level. 
1.3 POLYPHARMACOLOGY AND MECHANISM STUDY FOR TCM 
Systems biology is an emerging area of biology, which utilizes experimental and 
computational approaches to evaluate and integrate large datasets in a systematical way. Systems 
biology also examines and analyzes regulatory networks with large datasets, in order to identify 
how the elements are joined to form a functional system [22]. Polypharmacology, a concept that 
one or multiple drugs can modulate multiple targets to treat disease, is an important application 
of systems biology in drug discovery [22]. Polypharmacology might involve multiple drugs 
acting on multiple targets in the context of network regulating physiological responses in disease 
process [12]. So polypharmacology is very useful in the discovery of novel drugs and suitable 
combination medications for complex diseases, such as cancer, in which drugs act on multiple 
therapeutic targets in a complex pathological network. Systems pharmacology often use network 
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analysis of drug-target interaction as an approach [20]. On the other hand, polypharmacology is 
believed to reduce on-target and anti-target adverse effect, and drug resistance, thus improving 
drug safety, preventing side effects and drug tolerance [22]. Taken together, systems 
polypharmacology analysis can lead to new therapeutic directions with improvement on both the 
safety and efficacy of existing medications [23].  
Given the complex pathological mechanism and therapeutic pathways involved in 
cardiovascular diseases, polypharmacology analysis is often performed to understand the 
synergistic effect of drugs reacting with multiple therapeutic targets in the overlapping signaling 
pathways [24]. Polypharmacology analysis can not only help to unravel the mechanism of 
actions of primary targets for existing drugs in the context of a whole organism, but also predict 
possible off-target therapeutic and adverse effects [25] and guide combination therapy [26]. On 
the other hand, TCM is about herbal formulations with multiple herbs, involving multiple 
constituents, acting on multiple targets in overlapping therapeutic pathways to attain a 
synergistic effect with higher efficacy and reduced side effects to treat disease. Therefore, 
systems pharmacology offers an effective approach to evaluate polypharmacological effects of 
traditional Chinese herbal formula at the molecular level to explore the interactions between 
small chemical molecules and targets in a pathological system. Moreover, polypharmacology are 
often used with computational methods, such as fragment-based methods [27], Gaussian 
Ensemble Screening (GES) polypharmacology fingerprints [28], in silico polypharmacology [29], 
and data mining [11] to avoid the spending of large amount of cost and time. Herein, we perform 
a polypharmacology study combined with computational approaches to screen active 
components from the three herbs in SND, to predict and to validate their corresponding targets 
and pharmacological actions. 
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1.4 CARDIOVASCULAR DISEASES 
Cardiovascular diseases are the leading cause of death in the world (accounting for 31% 
in the distribution of all causes of death, as shown in Figure 2A) [30]，accounting for 28% in 
non-communicable diseases (NCD) [31] caused death worldwide. 
Cardiovascular diseases (CVDs) are a group of disorders of heart and blood vessels, 
including: coronary heart disease or ischaemic heart disease (e.g. heart attacks), cerebrovascular 
disease (e.g. stroke), peripheral arterial disease, rheumatic heart disease (damage to the heart 
muscle and heart valves caused by rheumatic fever), congenital heart disease (inherent 
malformations of heart structure), deep vein thrombosis, and cardiac arrhythmias. An estimated 
17.5 million people died from CVDs in 2012, representing 31% of all global deaths (Figure 2A) 
[32]. Among these deaths caused by CVDs, an estimated 7.4 million deaths were due to coronary 
heart disease (heart attack, accounting for 46% and 38% in cardiovascular diseases caused deaths 
for male and female respectively) and 6.7 million deaths were due to cerebrovascular disease 
(stroke, accounting for 34% and 37% in cardiovascular diseases caused deaths for male and 
female respectively), as shown in Figure 2C and 2D [30, 33]. 
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Figure 2. Distribution of Death  
(A) The distribution of all causes of death in the world per year in 2013; (B) The distribution of 
death caused by different non-communicable diseases (NCD); (C, D) The distribution of death 
caused by different cardiovascular diseases in female (C) and male (D). Data was collected from 
WHO website. 
 
 
A. 
C. 
B. 
D. 
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Heart attack, stroke, heart failure, myocardial infarction (MI), shock and other 
complications are mainly due to the failure of the blood supply to the heart, brain, and other 
tissues by the circulation, caused by the formation of blockage in blood vessels or the 
impairment of heart function. The causes of heart failure and other indications are usually the 
presence of a combination of some common risk factors, such as tobacco use, unhealthy diet and 
obesity, physical inactivity and harmful use of alcohol, hypertension, diabetes and 
hyperlipidemia [32, 34]. Although there are many different complications and disorders in 
cardiovascular diseases that can be treated with different drugs and corresponding targets, these 
disorders share similar risk factors and pathological pathways [35]. We can see from Figure 3, 
the protein targets involved in the SND indications, such as coronary disease, MI, shock, and 
heart failure, overlap each other and also overlap with these targets involved in other 
cardiovascular diseases. Thus, when we study some specific cardiovascular diseases, we would 
better evaluate CVD as a whole. 
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Figure 3. Targets for SND Related Indications and Other Cardiovascular Diseases  
Targets in pathological pathways of SND indications, including coronary heart disease, 
myocardial infarction, heart failure, shock, and arrhythmia, represent by pink nodes; the other 
targets related with the etiology for other cardiovascular diseases are in blue; the yellow large 
nodes stand different types of diseases. 
Abbreviations: CHD, coronary heart disease; MI, myocardial infarction; HF, heart failure. 
 
 
Sini Decoction has been widely used in China for centuries as a rescue in emergencies to 
treat some cardiovascular diseases, such as heart failure, MI, and congestive shock. Since it is 
hard to consider those diseases individually, we then just put all the therapeutic targets together 
as a database to study Sini Decoction. Instead, we considered the cardiovascular diseases as 
whole to study the molecular mechanism of SND. 
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2.0 METHODS AND MATERIAL 
 
 
2.1 CARDIOVASCULAR DISEASES DATABASE CONSTRUCTION 
 
2.1.1 Database Infrastructure  
 
CVDPlatform was rooted from our established web-interface molecular database 
prototype CBID (www.CBLIgand.org/CBID) [36], which is constructed with a MySQL 
(http://www.mysql.com) [37] database and an apache (http://www.apache.org/) web server, and 
implemented with our house chemoinformatics tools.  
 
2.1.2 Cardiovascular Disease Knowledgebase Construction 
 
CVD related proteins and genes. The candidate proteins related to cardiovascular 
diseases were data mined from literature and public database, including PubMed 
(www.ncbi.nlm.nih.gov/pubmed), PubChem (pubchem.ncbi.nlm.nih.gov/), DrugBank 
(http://www.drugbank.ca), Potential Drug Target Database (http://www.dddc.ac.cn/pdtd), 
Therapeutic Targets Database (http://bidd.nus.edu.sg/group/ttd/), ClinicalTrials.gov 
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(clinicaltrials.gov/) and PharmGkb (www.pharmgkb.org), up to 984 candidate proteins were 
collected, and their corresponding X-ray crystallographic structures were obtained directly from 
RSCB Protein Data Bank (www.rcsb.org/pdb) to build the CVD specific chemogenomics 
database (www.cbligand.org/CVD ). 
CVD pathways (currently 269 records). The CVD related pathways was achieved via 
the public database KEGG [38] (http://www.genome.jp/kegg/) and DrugBank [39] using our in 
house data-mining tools. 
CVD bioassays. The corresponding bioassays for the target genes and proteins, which 
are used to validate our prediction, have been collected from a batch of literature and public 
resource, like PubChem [40], CHEMBL [41], and DrugBank [39].  
2.1.3 Chemoinformatics Tools 
The CVDPlatform provides both chemogenomics and chemoinformatics data to explore 
the potential CVD targets and off-targets, ADME and toxicity profile, to evaluate molecular 
properties, as well as to calculate drug-likeness. We have implemented several chemoinformatics 
tools and powerful algorithms in the platform to assist CVD drug design and target 
identification, as showed below. 
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Figure 4. Overview of CVDPlatform HTDocking Procedure 
HTDocking. We constructed online high-throughput docking program in our 
CVDPlatform. HTDocking online program aims to explore multiple druggable therapeutic 
targets, their interacted small chemical compounds, and their potential pharmacology. We use 
AutoDock in this HT-Docking program to offer a multi-facet capability, high performance rate 
and enhanced accuracy [42]. It can provide predicted binding affinity values (ΔG values) for 
different poses of each compound in the binding pockets [43]. The docking score in the HT-
docking program is served as a measurement for the binding affinity. The calculation of docking 
score is pKi=-log (predicted Ki) and the predicted Ki=exp(ΔG*1000/(1.987191*298.15)) . We can rank the 
potential therapeutic targets for cardiovascular diseases according to the docking score from each 
protein structure. Top listed targets with higher docking scores may have higher binding affinity 
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or more chance to interact with our input compounds. The workflow of HTDocking is shown in 
Figure 4. 
2.2 COMPOUND LIBRARY CONSTRUCTION 
Based on previous studies on chemical analyses of Sini decoction (SND) [44], 347 
compounds were reported in SND, with 196 constituents in GU, 49 constituents in AC and 102 
constituents in ZO. We selected 40 representative compounds with diverse chemical structure, 
which have been identified and isolated, including 25 constituents in AC, 13 constituents in GU, 
and 2 constituents in ZO (as shown in Table 1). The structures were obtained from the Chemical 
Book (www.chemicalbook.com), NCBI PubChem database (www.ncbi.nlm.nih.gov/
pccompound), Scifinder [45] (http://scifinder.cas.org/scifinder), and saved to files in SDF format 
and SMILES format for further analysis.  
Table 1. Constituents and their chemical structures in SND 
Name Structure Name Structure 
1 Aconitine 
AC 
20 Benzoylnapelline 
2 Hypaconitine 21 Isobenzoylnapelline 
3 Mesaconitine 22 Higenamine 
OH
HO
HO
NH
 15 
4 Deoxyaconitine 23 Coryneine 
5 Pyroaconitine 24 Isotalatizidine 
6 Pyrohypaconitine 25 Salsolinol 
7 Pyromesaconitine 26 Glycyrrhizic Acid 
8 Benzoylaconine 27 Glycyrrhizin 
9 Benzoylhypaconine 28 Isoliquiritin 
10 Benzoylmesaconine 29 Liquiritigenin 
11 Benzoyldeoxyaconine 30 Glycyamarin 
12 Aconine 31 Isoliquiritigenin 
N O
O
O
HO
O
OH
O
O
O
O
N+
HO
HO
NH
HO
HO
O
HO OH O O
OH
OH
OH
HO
O
O
HO
OH
Table 1 continued
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13 Hypaconine 32 Glycyrrhetinic Acid 
14 Mesaconine 33 Glycyrol 
15 Neoline 34 Licoricidin 
16 Talatisamine 35 Iso-Glycyrol 
17 Fuziline 36 Glycyrrhetic Acid 
18 14-Acetyl-Talatisamine 37 Liquiritin 
19 Talatizidine 38 Glycyrin 
39 6-Gingerol 40  8-gingerol 
1-25 are from AC, 26-38 are from GU, 39 and 40 are from ZO 
OCH3
O O
HO OH
OCH3
O
HO
H3CO
OH
O
HO
H3CO
OH
Table 1 continued
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2.3 TARGET PREDICTION 
Molecular docking, which is commonly applied to rational drug discovery, is frequently 
used to predict the interaction between small molecules and its corresponding target proteins,. In 
this study, the molecular docking approach was applied to predict the possible interaction 
between the 40 components from SND and the 984 target proteins we collected in our database. 
All the docking studies were done by Sybyl-X (version 1.3, TRIPOS, Inc.), using co-
crystal structures of target proteins. The protein structures need a preparation process before 
docking, involving the addition of hydrogens, removal of co-crystallized ligands and water 
molecules, addition of charges, fixation of side chain amide and side chain bumps to optimize 
interaction with surrounding residues and group atoms, and stage minimization. The binding site 
of the target protein in molecular docking was defined according to the key residues and known 
ligand position reported in literature using Surflex-Dock. For each of the compounds, the 
proteins with docking score larger than 6 were selected as its potential targets.  
2.4 NETWORK CONSTRUCTION 
Construction of a target-compound network for a specific herb formula is helpful and 
reasonable to identify and further evaluate potential targets and synergistic effect of compounds 
in SND in the context of disease pathways. Cytoscape 3.0.2 was used to generate the network 
plot between targets and compounds in order to predict possible targets for synergistic effect and 
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to understand the underlying principle of herbal formulation. Cytoscape is a standard 
computational tool that is frequently used in the biological field to generate, analyze and 
visualize the graphical network, where nodes represent targets or compounds, and edges stand 
for interaction between targets and compounds. 
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2.5 EXPERIMENTS 
2.5.1 Effect of SND on Normal Heart Function Measured by Hemodynamic Index 
Figure 5. Overview of Experimental Procedure for Effect of SND on Normal Heart 
Function Measured by Hemodynamic Index 
All of the animal studies followed the relevant national legislation and local guidelines, 
and were performed at the Centre of Laboratory Animals of the Second Military Medical 
University (Shanghai, China). The surgical procedures were performed using the well-
established techniques. All surgeries were performed under 25% urethane anesthesia and all 
efforts were made to minimize suffering. Five Sprague-Dawley (SD) rats were anesthetized with 
an intraperitoneal injection of Urethane (1.4 g/kg, i.p.) and placed in a supine position on a table 
for the operations. The first polyethylene catheter connected to a pressure transducer, which was 
equipped with a polygraph, was inserted into the right carotid artery and then advanced into the 
left ventricle cavity to record left ventricular systolic (LVSP) and end-diastolic pressures 
(LVEDP) and heart rate (HR). The second polyethylene catheter was inserted into the lower 
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abdominal aorta through the left femoral artery to record systolic blood pressure (SBP), diastolic 
blood pressure (DBP). The third polyethylene catheter was placed in stomach fundus for drug 
administration. The HR, LVSP, LVEDP, SBP, DBP, MBP, maximal rate of pressure 
development (+dp/dt) and decline (–dp/dt) were analyzed by LabChart software. Thirty minutes 
after surgery, when the hemodynamic parameters are in stable, the rats were administrated 
Intragastrically with Sini Decoction. After 30 minutes, the hemodynamic parameters (HR, 
LVSP, LVEDP, SBP, DBP, MBP, maximal rate of pressure development (+dp/dt) and decline (–
dp/dt)) were recorded and analyzed to see whether SND can have effect on heart function of 
normal rats. 
2.5.2 Effect of SND and Compounds on Heart Function of HF rats 
Figure 6. Overview of Experimental Procedure for HF Model of Rats Induced by 
LAD Ligation and Drug Effect Evaluation 
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2.5.2.1 HF model of rats induced by LAD ligation and drug administration The surgical 
procedures were performed using the well-established technique. All surgeries were performed 
under diethyl ether anesthesia and all efforts were made to minimize suffering. Rats were 
anesthetized with diethyl ether and placed in a supine position on a table for the operations. The 
left anterior descending artery (LAD) was occluded. To prevent infection, rats were given 
penicillin (40.000 units) after the operation for 3 days. Fifty animals survived throughout the 
experiment, including 40 LAD rat and 10 sham rats (without ligation). Forty LAD rats were 
randomly divided into four groups, 10 in HF model (water), 10 in herbs group (SND, 5g/kg), 10 
in components group (three herbs extract, 15mg/kg) and 10 in compounds group (three active 
compounds, 1 mg/kg). All drugs were given through oral administration began at 4 weeks after 
surgery. The drugs were diluted with distilled drinking water and administered orally with a 
volume of 5mL/kg body weight once every morning for 4 weeks (Figure 5) [46] [2].  
2.5.2.2 Echocardiography assessment Echocardiography was performed 21 days after surgery 
according to reported methods. Ten rats from each group were anesthetized by intraperitoneal 
injection of 100 mg /kg ketamine. After cleaning the rat chest, the cardiac short axis (papillary 
level), left ventricle end-diastolic dimension (LVIDd), and left ventricle end-systolic dimension 
(LVIDs) were measured using a Visual Sonics Vevo770 machine equipped with 23 (or 30) MHz 
transducers to assess systolic function. The ejection fraction (EF) was calculated from the left 
ventricle end-diastolic volume (LVEDV) and the left ventricle end-systolic volume (LVESV) as 
EF% = [(LVEDV − LVESV)/LVEDV]×100. The data calculations were performed using a 
single blind method (Figure 6) [47, 48].  
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2.5.2.3 Morphometric analysis Myocardial tissues in the left ventricle (LV) of sacrificed rats 
(approximately 2 mm in thickness) were removed after echocardiography assessment. Samples 
were fixed in 4% pre-cooled paraform aldehyde for 72 h and embedded in paraffin for 
histological studies. Paraffin-embedded tissues were sectioned into slices about 5 mm 
thicknesses. Masson’s trichromatic stain was performed to assess myocardial fibrosis. Images 
were visualized under an optical microscope at ×400 magnification [49].  
2.5.3 The effect of Liquiritin on the arrhythmia induced by Aconitine (AC) 
Male SD rats weighing 280-300 g were equally divided into two groups randomly: A 
(AC) and B (AC and Liquiritin). SD rats were anesthetized with an intraperitoneal injection of 
urethane (1.4 g/kg, i.p). The rats were intravenously injected with the normal saline in group A, 
and with 4 mg/kg Liquiritin in group B. After 5 min, 10µg/ml aconitine was injected to the rats 
in a constant speed of 0.1ml/min. The cardiac function test was performed on the PowerLab 8/35 
(AD instrument, Australia), and the rats were connected to PowerLab through three 
electrocardiograph electrodes. The electrocardiogram was recorded to show the time of the 
appearance of premature beats, ventricular tachycardias and cardiac arrest, and to calculate the 
dosage of aconitine, at which could lead to premature beats, ventricular tachycardias and cardiac 
arrest [50].  
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Male SD rats weighing 280-300 g were equally divided into four groups randomly: A 
(aconitine (AC), 10ug/kg), B (AC, 10ug/kg, and 6-gingerol, 70ug/kg), C (AC, 5ug/kg), and D 
(AC, 5ug/kg, and 6-gingerol, 35ug/kg). SD rats were anesthetized with an intraperitoneal 
injection of Urethane (1.4 g/kg, i.p.). The first polyethylene catheter connected to a pressure 
transducer, which was equipped with a polygraph, was inserted into the right carotid artery and 
then advanced into the left ventricle cavity to record left ventricular systolic (LVSP), end-
diastolic pressures (LVEDP) and heart rate (HR). The second polyethylene catheter was inserted 
into the lower abdominal aorta through the left femoral artery to record systolic blood pressure 
(SBP), diastolic blood pressure (DBP), and medium blood pressure (MBP). The third 
polyethylene catheter was connected with a needle that inserted into the femoral vein for 
intravenous drug administration. The HR, LVSP, LVEDP, SBP, DBP, MBP, maximal rate of 
pressure development (+dp/dt) and decline (–dp/dt) were analyzed by LabChart software. Thirty 
minutes after surgery, when the hemodynamic parameters are in stable, normal saline was 
injected to the rats in group A and C, and 70ug/kg and 35ug/kg 6-gingerol were injected to rats 
in group B and D respectively. After 5 minutes, the rats were intravenously injected with the 
10µg/ml aconitine in group A and B, and with 5µg/ml aconitine in group C and D. Then after 30 
minutes, the hemodynamic parameters (HR, LVSP, LVEDP, SBP, DBP, MBP, maximal rate of 
pressure development (+dp/dt) and decline (–dp/dt)) were recorded and analyzed, if they were in 
stable, to evaluate whether 6-gingerol can improve the effect of aconitine on heart function. 
2.5.4 The effect of aconitine (AC) combined with 6-gingerol on heart function 
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Figure 7.  The Overview for Experimental Procedure of Validation of Aconitine Acting on 
Beta-1 Adrenergic Receptor 
2.5.5 The validation of predicted targets for the effective compounds in SND 
2.5.5.1 The validation of aconitine acting on beta-1 adrenergic receptor  
SD rats were equally divided into four groups randomly: A (normal saline (NS) and AC), 
B (Propranolol (PRO) and AC), C (PRO and SND), and D (propranolol and NS). As described in 
2.5.5，SD rats were anesthetized with an intraperitoneal injection of urethane (1.4 g/kg, i.p), the 
cardiac function was performed on the PowerLab 8/35 (AD instrument, Australia), and the rats 
were connected to PowerLab through three electrocardiograph electrodes to record the 
hemodynamic index HR, LVSP, LVEDP, SBP, DBP, MBP, maximal rate of pressure 
development (+dp/dt) and decline (–dp/dt) was recorded by PowerLab, and analyzed through 
Labchart software to validate whether the effective compounds in SND agitated Beta adrenergic 
receptor. (Figure 7) Thirty minutes after surgery, the rats were intravenous injected with the 
propranolol in group B, C, and D after the hemodynamic condition is stable. After 5 min, 10 
µg/ml aconitine, SND, and saline were injected to the rats in a constant speed. After 30 min, the 
hemodynamic parameters were then recorded and analyzed when the blood pressure was stable 
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to see whether propranolol can block the effect of SND and aconitine on heart function in rats, in 
order to validate whether the effective compounds in SND agitated beta-1 adrenergic receptor 
(Figure 7).  
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3.0 RESULTS 
3.1 CARDIOVASCULAR DISEASES RELATED TARGETS AND DRUGS 
CVDPlatform (www.cbligand.org/CVD) archived 984 cardiovascular diseases related 
target proteins, corresponding with 924 FDA-approved and clinical trial CVD drugs, 276 
cardiovascular related pathways and 2080 active chemical compounds associated with therapeutic 
targets of CVDs, and 350765 references. 
Figure 8. Summary of CVD related targets 
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Figure 8 illustrated detailed target information about the cardiovascular diseases database 
(CVDPlatform). The majority of CVD target proteins are 440 enzymes, including angiotensin 
converting enzyme (ACE), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), renin 
(REN), and prothrombin (Coagulation factor II, FII). In addition, 123 membrane receptors, such 
as beta-1 adrenergic receptor (ADBR1), beta-2 adrenergic receptor (ADBR2), muscarinic 
acetylcholine receptor M1, M2, M3 (ACM1, 2, 3), alpha-1 adrenergic receptor (ADAR1), type-1 
angiotensin II receptor (AGTR1), and 81 ionic channels, such as voltage-dependent N-type 
calcium channel subunit alpha-1 (CAC1) are also included in these 984 target proteins.  
Statistical analysis was performed on the number of drugs in the different development 
phases according to their therapeutic targets. The corresponding targets were ranked according to 
the total number of drugs, and the top 20 targets were listed in Figure 9.  Not surprisingly, we 
can easily found the well-known therapeutic targets with anti-cardiovascular disease drugs in the 
market. For example, 12 approved drugs act on beta-1 adrenergic receptor to decrease heart rate, 
myocardia contraction and conduction to treat hypertension, heart failure, shock, and other 
complications; several approved drugs act on potassium, sodium, and calcium channels to treat 
stroke, cerebral hemorrhage, coronary artery disease, heart failure, hypertension, arrhythmias, 
and other disorders; some well-known anti-hypertension agents act on targets in renin-
angiotensin-aldosterone system, such as angiotensin converting enzyme, angiotensin receptor 
type I, and renin, to treat heart failure and coronary artery disease. Moreover, some relative new 
targets have attracted more attention recently, with larger percentage of drugs in phase 1 and 
phase 2 compared with traditional targets, such as Endothelin-1 receptor (EDNRA) and renin 
(Renin) 
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Figure 9. Drugs and Their Targets in Different Development Phases  
These approved and clinical trial CVD drugs were classified by different phases, distinguished 
by distinct colors. The red and blue columns indicate the approved and discontinued CVD drugs, 
respectively. The orange, light blue, purple and green lines denote clinical trial drugs in phases I, 
II, II and IV respectively. 
Abbreviations: ADRB1, Beta-1 adrenergic receptor; ADRB2, Beta-2 adrenergic receptor; KCN, 
Potassium channel; ADRA1, Alpha-1 adrenergic receptor; SCN, Sodium Channel; ACE, 
Angiotensin Converting Enzyme; CACN, Voltage-dependent L-type calcium channel; FV, 
Coagulation Factor V; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase;	  ADRA2, 
Alpha-2 adrenergic receptor; EDNRA, Endothelin-1 receptor; REN, Renin; AGTR, Angiotensin 
II receptor; ADRB3, Beta-3 adrenergic receptor; HTR, serotonin receptor; PDE3, cGMP-
inhibited 3',5'-cyclic phosphodiesterase; FII, Coagulation Factor II; TNF-alpha, Tumor necrosis 
factor alpha; HRH1, Histamine H1 receptor, COX-2, Prostaglandin G/H synthase 2 
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Interestingly, some targets have a number of drugs that have already been withdrawn 
from the market or discontinued in the early phase of clinical trials. The ADBR1, ion channels, 
and ACE are targets with both the strong therapeutic effect and a toxic potential, having almost 
equal number of approved and withdrawn drugs. For instance, ADBR1 have strong cardiac 
inotropic effect, which is not only important for its therapeutic effect but also poisonous 
sometimes for a long time use. However, the cardiovascular disease agents are often used in a 
long term to control the blood pressure, lipid profile, and plasma glucose level within a normal 
range in order to reduce the risk of many cardiovascular complications, such as heart failure, 
heart attack, and stroke. Some long-term side effects that cannot be recognized in the early 
clinical trial might be found in patients after entering into market. Also, the criteria for the 
acceptable drug toxicity are different for cardiovascular diseases and some more fetal chronic 
diseases like cancers. Some toxicity effects that are tolerated for anticancer drugs may not be 
allowed for anti-CVD agents (Figure 9). 
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Figure 10. Therapeutic Targets for MI and HF ranked by the number of drugs 
These approved and clinical trial drugs were classified by treatment for MI and HF, 
distinguished by distinct colors. The red columns indicate MI drugs; the blue columns denote HF 
drugs. The targets are ranked by the total number of drugs for the treatment of two diseases. 
Abbreviations: MI, myocardial infarction; HF heart failure; ADBR1, beta-1 adrenergic 
receptor; ACE1, angiotensin converting enzyme1; ADBR2, beta-2 adrenergic receptor; PDE5A, 
cGMP-specific 3', 5'-cyclic phosphodiesterase; FX, coagulation factor X; HMGCR, 3-hydroxy-
3-methylglutaryl-coenzyme A reductase; COX-2, Prostaglandin G/H synthase 2; PDE4A, 
cAMP-specific 3',5'-cyclic phosphodiesterase 4A; DPP4, Dipeptidyl peptidase-4; ADBR3, beta-3 
adrenergic receptor; THB1, truncated haemoglobin; THA, Thermosipho africanus; FII, 
coagulation factor II; REN, renin; COX-1, Prostaglandin G/H synthase 1; uPA, Urokinase-type 
plasminogen activator; tPA, Tissue-type plasminogen activator; NOSi, Nitric oxide synthase, 
inducible; ACES, Acetylcholinesterase; PLG, Plasminogen receptor; MAOB, Amine oxidase 
[flavin-containing] B; MAOA, Amine oxidase [flavin-containing] A; ATIII, Antithrombin III; 
APN, Aminopeptidase N 
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Figure 11. CVD Related Pathways in CVDPlatform 
The CVD related pathways were plotted according to the number of CVD targets involved. (A) 
The top 20 pathways with more than 20 CVD targets involved were listed. (B) The number of 
CVD drugs in a pathway was divided by the total number of the targets in the pathway. 
Abbreviation: PI3K-AKT, PI3K-Akt signaling pathway; CAMP, cAMP signaling pathway; 
CACN, Calcium signaling pathway; PLATELET, Platelet activation; VEGFR, Vascular smooth 
muscle contraction; ADR, Adrenergic signaling in cardiomyocytes; THR, Thyroid hormone 
signaling pathway; CHO, Cholinergic synapse; 5HT, Serotonergic synapse; MM, Mutiple 
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myeloma; TRP, Inflammatory mediator regulation of TRP channels; INSULIN,Insulin signaling 
pathway; AMPK, AMPK signaling pathway; CR, Circadian rhythm; AD, Alzheimer's disease; 
DILATED CM, Dilated cardiomyopathy; PRO, Protein digestion and absorption; HCM, 
Hypertrophic cardiomyopathy; ARVC, Arrhythmogenic right ventricular cardiomyopathy; 
PPAR, Peroxisome proliferator-activated receptor signaling pathway. 
In addition, these targets emphasized in the cardiovascular diseases, are also in the top list 
for the targets involved in the specific indications for SND, such as heart failure and myocardial 
infarction, like ADBR1, ACE, ADBR2, HMGCR, indicating the reliability to use cardiovascular 
diseases as a whole to inspect the therapeutic effects and targets for SND (Figure 10). 
The statistic of CVD targets was also plotted according to the pathways the CVD targets 
involved (as shown in Figure 11). Since some pathways might contain much more targets than 
other pathways, using the number of CVD therapeutic targets involved in different pathways, as 
a measurement of correlation with CVD seems not fair. Thus, we used the total number of 
proteins in a pathway to divide the number of CVD targets involved in that pathway, as a 
measurement of correlation between that pathway and CVD, as shown in Figure 11B. Figure 
11A shows the top list pathways with more than 20 targets involved. Figure 11B shows the top 
list pathways with a higher ratio of targets involved in the CVD treatment. Two groups of 
pathways occupy a large percentage of the top list pathways: pathways regulating blood pressure 
and pathways involved in the ADME of protein, fat, and carbohydrates. Firstly, we found many 
pathways involved in the regulation of blood pressure were on the top list pathways, such as 
cholinergic and adrenergic pathway in automatic nervous system (ANS), renin-angiotensin-
aldosterone system pathways (RAAS), calcium signaling pathway, and pathways directly acting 
on heart to control heart rhythm and cardiac muscles. Secondly, pathways that regulate plasma 
glucose and lipid level play an important role in treatment of CVD, such as protein digestion and 
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absorption, insulin signaling pathway, fat digestion and absorption, and Peroxisome proliferator-
activated receptor (PPAR) signaling pathway. Furthermore, we can see 76% targets in the 
Alzheimer’s disease pathological pathways are also discovered as therapeutic targets for 
cardiovascular diseases. 
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3.2 CVDPLATFORM VALIDATION USING POLYPHARMACOLOGY ANALYSIS OF 
ANTI-CVD DRUGS 
Figure 12. Validation of CVDPlatform 
Validation of CVD database using polypharmacology analysis of FDA-approved anti-CVD 
drugs. The large circles (cyan) represent FDA-approved CVD drugs (Atorvastatin, Fluvastatin, 
Pravastatin, Lovastatin, Cilazapril, Trandolapril, Aliskiren, Argatroban, and Apixaban). Each 
drug is linked to its predicted targets by edges. Among them, the blue nodes and edges denote 
the known therapeutic targets for the drugs and their interactions. Yellow nodes represent 
predicted potential targets without experimental validation and they are linked by cyan and pink 
edges to their corresponding drugs. 
Abbreviation: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; ACE, Angiotensin-
converting enzyme; ATIII, Antithrombin-III; FII, coagulation factor II; FIII, coagulation factor 
III; FX, Coagulation factor X; FXa, Coagulation factor Xa; FXI, Coagulation factor XI; REN, 
Renin 
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As a validation procedure, we used our established computational chemogenomics 
methods in CVD database to predict the potential targets for 9 FDA-approved drugs, including 
four HMG CoA reductase (HMGCR) inhibitors (Atorvastatin, Fluvastatin, Pravastatin, and 
Lovastatin), two angiotensin converting enzyme (ACE) inhibitors (Cilazapril and Trandolapril), 
a renin (REN) inhibitor (Aliskiren), a prothrombin (FII) antagonist (Argatroban), and a 
coagulation factor X (FX) inhibitor (Apixaban). The potential target proteins for the nine anti-
CVD drugs were predicted and ranked by docking scores. These associations were plotted as a 
polypharmacological interaction network (Figure 12).  
Firstly, we compared our predicted drug-target connections against the reported ones. Not 
surprisingly, the known therapeutic targets for these agents such as HMGCR, ACE, REN, FX, 
and FII are ranked on the top of the corresponding predicted targets list in our results. For 
example, HMGCR is the protein ranked the first in the lists of target proteins for Pravastatin, 
Lovastatin, and Fluvastatin; prothrombin was distinguished from other targets with higher score 
ranked the first for Argatroban; Aliskiren (renin ranked the first) and Cilazapril (ACE ranked the 
third) also have their known therapeutic targets easily identified on the top lists. Moreover, our 
predicted binding affinities for these targets were consistent with the bioactivity data via 
comparing the docking scores with the experimental Ki or Kd values (Table 2). Furthermore, 
some additional predicted interactions were also validated by bioassays reported in literature or 
PubChem, indicating the reliability of the HTDocking program in CVDPlatform (Table 2). In 
addition, the other predicted associations, though no experimental validation so far, could be 
clues for the discovery of novel targets and indications of the existing drugs. 
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Table 2.  Comparison of the Experimental Data and the Predicted Results 
Target Drug Docking 
Score 
Exp 
pKi 
Exp 
Ki(nM) 
Reference/ PubChem ID 
Coagulation Factor Xa Apixaban 8.75  9.09 0.8 J. Med. Chem., (2007) 
50:22:5339 
Coagulation Factor II Argatroban 8.04 8.39 4 J. Med. Chem., (2003) 
46:17:3612 
Coagulation Factor III Argatroban 7.27 7.40 39 J. Med. Chem., (2003) 
46:17:3612 
3-Hydroxy-3-Methylglutaryl-
Coenzyme A Reductase 
Lovastatin 7.52 8.22 6 AID83293 
Coagulation Factor Xa Argatroban 6.26 5.27 5300 AID766528 
Angiotensin-Converting 
Enzyme 
Captopril 9.12 8.76 1.7 AID37801 
Renin Captopril 8.98 8.76 1.7 AID198995 
Coagulation Factor II  Apixaban 6.54 5.50 3100 AID302354 
Cholinesterase Lovastatin 7.22 5.95 1100 AID1093611 
3-Hydroxy-3-Methylglutaryl-
Coenzyme A Reductase 
Fluvastatin 11.83 IC50=28nM Bioorg. Med. Chem. Lett., 
(2005) 15:4:1027 
Renin Aliskiren 6.58 IC50=0.5nM AID371780 
3-Hydroxy-3-Methylglutaryl-
Coenzyme A Reductase 
Atorvastatin 10.57 IC50=0.227nM AID625271 
3-Hydroxy-3-Methylglutaryl-
Coenzyme A Reductase 
 
Pravastatin 8.37 IC50-5.59nM AID625271 
Angiotensin-Converting 
Enzyme 
Trandolapr
il 
8.53 IC50=0.93nM AID39767 
Urokinase-Type Plasminogen 
Activator Precursor 
Fluvastatin 7.69 Potency=56.2nM AID540303 
Glucocorticoid Receptor Fluvastatin 7.32 Potency=264.8nM AID720692 
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The discovery of novel combination therapies, with improved pharmacological 
therapeutic effects and reduced side effects, is another application of poly-pharmacology analysis 
for approved drugs on the market [51]. According to clinical studies and literature reports, renin 
inhibitor (Aliskiren) is often used with angiotensin converting enzyme (ACE) inhibitors 
(Ramipril, NCT01432106; Lisinopril, NCT00994253; Enalapril, NCT00853658), and / or 
angiotensin II receptor (AGTR) inhibitor (Valsartan, NCT01432106) to attain enhanced effects 
on hypertension regulation, heart failure (HF) and coronary diseases control. There are four 
targets in RAAS: angiotensinogen (AGT), renin, ACE, and angiotensin II receptor type 1 
(AGTR). Renin converts angiotensinogen to angiotensin I. Angiotensin I is then catalyzed by 
ACE to form angiotensin II. Angiotensin II is the most potent compound in the system acting on 
AGTR to regulate blood pressure. The effect of these four targets can be amplified when they 
work together to treat disease.  So we can also predict the combination use of Aliskiren with 
Cilazapril or Trandolapril for hypertension treatment. HMGCR inhibitors, like Atorvastatin, are 
reported to be used in combination with ACE inhibitors (Ramipril, NCT01321255; Enalapril, 
NCT01271985) and AGTR antagonists in clinical trials to treat some complications in 
cardiovascular diseases. The combination medication of ACE inhibitors (Cilazapril and 
Trandolapril) and HMGCR inhibitors (Atorvastatin, Fluvastatin, Pravastatin, and Lovastatin) 
may reduce blood pressure, LDL and cholesterol level, thus lowering the risk for heart attack and 
stroke.  
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3.3 POLYPHARMACOLOGY OF TARGETS OF SND COMPOUNDS 
3.3.1 Target Prediction 
As shown in Table 2, 33 targets related to the therapeutic effect of SND were linked with 
31 components by molecular docking. Components deoxyaconitine (4), neoline (15), 
talatisamine (16), 14-acetyl-talatisamine (18), talatizidine (19), coryneine (20), isoliquiritigenin 
(31), and glycyrrhetic acid (36) were ruled out due to low affinity to all the candidate proteins. 
Most candidate target proteins are shared by more than one component. ADRB1, ADRB2, 
M3AChR (M3 muscarinic acetylcholine receptor), FII, HMGCR (3-hydroxy-3-methylglutaryl-
coenzyme A reductase), ACE, and renin can be good examples of potential targets with large 
number of connected components, 20, 11, 11, 12, 11, 10, and 14 respectively. These potential 
targets might play a critical role for SND to achieve its therapeutic effects. Actually, only 10 
target proteins have just one corresponding component, suggesting a high rate of cross-targets 
shared by multiple components in SND formulation, which magnifies the possibility for 
synergistic effect. We built a network for target-compound interaction for SND to investigate the 
synergistic effect of the SND. 
3.3.2. Network construction 
A TCM prescription usually contains several herbs. The formula is based on the principle 
of “Jun-Chen-Zuo-Shi”， also known as “emperor-minister-adjuvant-courier”. “Jun” (emperor) 
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is mainly applied to treat the primary symptoms of the disease; “Chen” (minister) is used to 
reinforce the effects of “Jun” or deal with contingent indications; “Zuo” (adjuvant) plays an 
important role in lessening or eliminating toxic side effects of “Jun” or “Chen” and aids to cure 
collateral symptoms; “Shi” (courier) assists in transferring or leading other herbs to the target 
organs or tissues [52]. Unfortunately, the essential components and corresponding targets have 
not been identified in many formulae including SND, while precise mechanisms remain to be 
addressed by a molecular approach. We attempted to analyze and interpret the compatibility 
mechanism of SND formulation through the construction of a target-compound network. 
As illustrated in Figure 13, the bilateral graphical network incorporated 64 nodes and 
178 edges, where the edges encode interaction and the nodes represent potential targets (in 
squares) or compounds (in circles). The target proteins with smaller sizes, outside the main 
circle, are only targeted by one herb. Potential targets in the main circle are linked to multiple 
compounds, and might exert synergistic therapeutic efficacies [53]. To further evaluate the 
effects of three herbs in the SND formulation, we divided the components by their origin herbs 
and distinguish them by different colors: 1 to 25 are from AC (in light blue), 26 to 38 are from 
GU (in fuchsias), 39 and 40 are from ZO (in dark blue).  
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Figure 13. Network for Compound-Target Interaction 
Thirty-one compounds were predicted to interact with 33 potential protein targets. The squares 
represent the targets, while the circles represent the compounds. Different color was applied to 
represent components from different herbs and potential targets from different physiological 
system: components from AC in light blue, GU in magenta, ZO in deep blue; targets from RAS 
system in yellow, autonomic nervures system in rubber red, coagulation system in purple, targets 
related to lipid metabolism in light blue, and targets relevant to immune and inflammatory 
process in light green. In addition, the sizes of the targets (squares) refer to the number of 
interactions with compounds. The edges stand for interactions: blue dashed edges stand for 
interactions without validation; green solid edges stand for validated interactions. 
Abbreviation: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; AChE, Acetyl 
cholinesterase; .ACE, Angiotensin-converting enzyme; AGT, Angiotensinogen; ATIII, 
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Antithrombin-III; FII, coagulation factor II; FVII, coagulation factor VII; FX, Coagulation factor 
X; KCN, Potassium channel; KvCN, Potassium voltage-gated channel; PAF, Platelet activating 
factor; SCN, Sodium channel; M3AChR, M3 muscarinic acetylcholine receptor; M2AChR, M2 
muscarinic acetylcholine receptor; ADRB1, Beta1 adrenergic receptor; ADRB2, Beta2 
adrenergic receptor; PPARG, Peroxisome proliferator-activated receptor gamma; GSK3B, 
Glycogen synthase kinase 3 beta; GCR, Glucocorticoid receptor; COX-2, Prostaglandin G/H 
synthase 2. 
3.3.3 Select representative active constituents for each herb 
In order to study the specific molecular mechanism, we needed to narrow down the 
compounds into three representative ones for bioassay tests. We selected liquiritin, 6-gingerol, 
and aconitine as active constituents to represent licorice, ginger, and aconitum respectively, 
according to three criteria: first, the corresponding targets for the three constituents can represent 
most targets of all the ingredients, especially the important targets with therapeutic effect we 
used in validation, such as beta-1 adrenergic receptor; second, the three constituents need to be 
tested, identified, and isolated from herbs extract previously, so that they are available to be 
obtained and used in further experimental validation. We then constructed a network for the 
interaction between three selected compounds (liquiritin, 6-gingerol, and aconitine) and their 
corresponding predicted targets, as shown in Figure 7. 
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Figure 14. Interaction Network of Representative Compounds and Their Targets 
The large circles (cyan) with chemical structures represent the three representative constituents 
(Liquritin, 6-gingerol, and Aconitine) we selected for each of three herbs (Liquorice, Ginger, and 
Acontium) in Sini Decoction. Each constitute is linked to its predicted targets, represented by 
nodes. Among them, the green nodes and edges denote the known targets of the compounds. 
Pink nodes represent new predicted targets without validation and they are linked to their 
corresponding constituents by blue dashed edges. 
Abbreviation: HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; AChE, Acetyl 
cholinesterase; ACE, Angiotensin-converting enzyme; AGTR, Angiotensin II receptor; ATIII, 
Antithrombin-III; ADRB1, Beta1 adrenergic receptor; ADRB2, Beta2 adrenergic receptor; 
PPARG, Peroxisome proliferator-activated receptor gamma; GSK3B, Glycogen synthase kinase 
3 beta; COX-2, Prostaglandin G/H synthase 2. 
w 
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3.3.4 Detailed Docking Information for Selected Constituents and Targets 
Figure 15. Detailed Interaction Mode of ACE with Lisinopril and 6-Gingerol 
Interaction of ACE (angiotensin converting enzyme) (PDB Entry: 1O86) [41] with lisinopril 
(ACE inhibitor) (A) in co-crystal structure and with 6-gingerol (B) predicted by molecular 
docking. Hydrogen-bond bindings are indicated by red dashed line with measured distance, and 
some hydrophobic interactions (especially the π-π interactions) are displayed as dark blue dashed 
line with measured distance. Residues are shown in green, Lisinopril in blue, and 6-gingerol in 
yellow. 
The interaction mode of 6-gingerol with ACE, comparing to ACE with ACE inhibitor 
Lisinopril is shown in Figure 15. We can see that Lisinopril has a carboxylic acid and 6-gingerol 
has a ketone, they are located in a position close to several hydrogen donors from three amine 
acids residues: Tyr520, Gln281, and Lys511. Both these two compounds form four hydrogen 
bonds with these residues at a range of distance from 1.5Å to 3.2Å, and from 2.0Å to 3.7Å, 
respectively. Additionally, Lisinopril forms two hydrogen bonds with the hydroxyl in Tyr523 
A. B. 
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and the ketone in Ala354, and have a π-π interaction with Tyr523, contributing to its high 
binding affinity (Ki=0.27nM). On the other hand, 6-gingerol has two complementary hydrogen 
bonds with Glu162 and Tyr523 in a distance of 1.7Å and 2.5 Å respectively, indicating a similar 
binding affinity between ACE and Lisinopril [54].  
Figure 16. Detailed Interaction Mode of MAOB with Coumarin Analog and Liquiritin  
Interaction information of MAOB (monoamine oxidase B) (PDB Entry: 2V61) [55] with 
coumarin analog (A) in co-crystal structure and with liquiritin (B) predicted by molecular 
docking. Hydrogen-bond bindings are indicated as red dashed line with measured distance, and 
some hydrophobic interactions are displayed as dark blue dashed line with measured distance. 
Residues are represented in green, liquiritin in yellow, and coumarin analog in blue. 
A. B.
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As shown in Figure 16, liquiritin and coumarin analog was located into the same 
pocket with the similar poses and interact with similar residues. Both liqiuritin and couramrin 
analog form three hydrogen bonds with the hydroxyl groups in residue Tyr326, the aldehyde 
groups in Tyr435 and Cys172. Additionally, Liquiritin forms another hydrogen bond with 
Pro102, which may enhance its binding affinity. 
. 
We can see from Figure 17, mevastatin, known as HMGCR inhibitor, interacts with 
residues in both chain A and chain B in the HMGCR tetramer crystal structure (PDB Entry: 
1HW8). When being positioned into the same pocket as mevastatin, aconitine has a similar 
binding pose and interacts with similar residues with mevastatin, such as residues Glu559, 
Asn755, His752, Leu853, and Lys735 in chain A, and residues Ser661, Lys691, Ser684, Asp690, 
and Arg590 in chain B. However, 6-gingerol and liquiritin, which have a smaller molecular size, 
cannot occupy the large pocket between two chains, and they mainly interact with residues in 
chain B, such as Ser661, Lys691, Ser684, Asp690, and Arg590, while merely forming a few 
hydrophobic interactions with chain A. Thus in accordance with less interaction with chain A, 6-
gingerol and liquiritin may have lower binding affinity or less chance to interact with HMGCR 
compared with mevastatin and aconitine.  
To be specific, both 6-gingerol and liquiritin form three hydrogen bonds respectively 
with residues Asp690, Ser661, and Arg590 in chain B; the phenolic hydroxyl in liquiritin also 
forms a hydrogen bond with Ser684. The binding modes of Mevastatin and Aconitine are similar 
with each other. Both of them formed hydrogen bonds with Lys735, Arg590, Ser661, and 
Leu853, but they had slight difference: the distances for Aconitine to form hydrogen bonds with 
Ser661 (2.4Å) and Arg590 (2.7Å) are shorter than Mevastatin (3.8Å and 3.9Å), while the 
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distance between Aconitine (1.7Å) and Lys735 is farther than Mevastatin (3.3Å), indicating that 
Aconitine is closer to chain B than Mevastatin. Mevastatin and Aconitine had hydrophobic 
interaction with similar residues, such as Lys692 in chain A. However, the interaction mode for 
Mevastatin also shown its identical characteristic, which distinguished Mevastatin form other 
Aconitine.  Mevastatin formed two hydrogen bonds with the carboxylic acid in residues Ser684 
(in chain B) and Glu559 (in chain A) respectively, and formed other hydrogen bonds with amide 
in Asn755, and guanidine in Arg690. In contrast, Aconitine could not have hydrogen binding 
with Asn755, Arg690, Ser684, and had less change to form one hydrogen bond with the 
carboxylic acid in Glu559 with a long distance (4.4Å). However, Aconitine might form three 
additional hydrogen bonds with Arg590 with a distance of 3.4Å, 2.3Å, and 2.0Å, while 
Mevastatin did not. 
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Figure 17. Interaction Mode of HMGCR with Mevastatin and Constituents in SND 
Interaction information of HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) (PDB 
Entry: 1HW8) [56] with Mevastatin (A) in co-crystal structure, and with aconitine (B), 6-
gingerol (C), and liquiritin (D) predicted by molecular docking. Hydrogen-bond bindings are 
indicated by red dashed line with measured distance, and some hydrophobic interactions are 
displayed as dark blue dashed line with measured distance. Residues are represented in green, 
mevastatin in yellow, liquiritin, 6-gingerol, and aconitine in blue. 
A. 
D. 
B. 
C. 
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Figure 18. Interaction Mode of PPARG with Retinoic Acid and Glycyrrhetinic Acid  
Interaction information of PPARG (PDB Entry: 1FM6) [57] with (9cis)-retinoic acid (A) in co-
crystal structure and with glycyrrhetinic acid (B) predicted by molecular docking. Hydrogen-
bond bindings are indicated as red dashed line with measured distance, and some hydrophobic 
interactions are displayed as dark blue dashed line with measured distance. 
We can see from Figure 18, glycyrrhinic acid (B) (2.0Å, 2.1Å, and 2.7Å) formed three 
same hydrogen bindings with residues Arg316 and Ala327 within a distance of 2.7 Å, which are 
similar as the co-crystal ligand (9cis)-retinoic acid (A) (2.6Å, 2.6Å, and 3.1Å). In contrast to 
(9cis)-retinoic acid, glycyrrhinic acid also forms an additional hydrogen bond with Phe346 with 
a distance of 2.4 Å, indicating a higher binding affinity. Moreover, glycyrrhinic acid fits into the 
same pocket with similar poses as (9cis)-retinoic acid, and forms hydrophobic interactions with 
almost the identical residues around them, such as Val342, Phe346, Ile 268, Leu326, Leu309, 
and Gly436. 
A. B. 
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Figure 19. Interaction Mode of AChE with Dihydrotanshinone I and Constituents in SND  
Interaction information of AChE (Acetylcholinesterase) (PDB Entry: 4M0E) with 
Dihydrotanshinone I (A, in blue) in co-crystal structure, and with 6-gingerol (B, in red), 
higenamine (C, in red), and liquiritin (D, in red) predicted molecular docking. Hydrogen bonds 
are indicated as red dashed line with measured distance, and some hydrophobic interactions are 
displayed as dark blue dashed line with measured distance. 
A. B. 
C. D. 
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As shown in Figure 19, 6-gingerol, liquiritin and higenamine fitted into the same pocket 
with similar poses compared with Dihydrotanshinone I in the co-crystal structure. The benzoyl 
ring in 6-gingerol, the aromatic rings in liquiritin and higenamine formed π-π interactions with 
benzoyl ring in residue Tyr341 in AChE within a distance of 4 Å. This observation was in 
agreement with interaction mode between Dihydrotanshinone I and AChE in the co-crystal 
structure (PDB Entry: 4M0E). Additionally, Liquiritin also formed another π-π interaction with 
residue Trp286 in AChE, in accordance with π-π interaction of Dihydrotanshinone I and Trp286 
in co-crystal structure. Moreover, liquiritin, as well as 6-gingerol formed hydrogen bonds with 
residues Phe295, Tyr124, and Tyr134, similar to Dihydrotanshinone I in the co-crystal structure. 
Liquiritin formed three additional hydrogen interactions with Trp286, Trp285 and Leu339 in 
AChE in a distance of 2.3 Å and 3.0 Å individually. Although higenamine did not form the π-π 
interaction with Trp286 and some hydrogen bonds with Tyr 341 and Tyr124 as the ligand in co-
crystal structure did, it formed two additional hydrogen interactions with carboxyl groups in 
Leu339, Trp285, and Trp286 respectively to recoup the potential binding affinity. As for 6-
gingerol, its hydroxyl group and ketone group interacted with Phe295 and Ser293 respectively, 
forming two hydrogen bonds, to compensate the loss of π-π interaction with Trp286. 
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3.3.5 Homology Model and Docking of Beta-1 Adrenergic Receptor 
Figure 20. Homology Modeling and Docking Analysis of Beta-1 Adrenergic Receptor.  
(A) Homology model for beta-1 adrenergic receptor and the binding site we defined by the key 
residues in reports. (B) Detailed interaction information for docking analysis for aconitine and 
beta-1 adrenergic receptor. 
Since ADBR1 has no available crystal structure, we built homology model for human 
beta-1 adrenergic receptor based on the crystal structure of human beta-2 adrenergic receptor 
(PDB Entry: 2R4R) co-crystal structure with 65% sequence similarity (Shown in Figure.20A). 
The pocket is defined according to the key residues in literature reports as shown in Figure 20A. 
The detailed docking mode is shown in Figure 20B that the ketone and amide in aconitine can 
form hydrogen bonds with the amide in Asn368 and Phe169 respectively. The hydroxy groups in 
A B
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aconitine can also form hydrogen binding with residues Asn257, Asp168, and Asp89 
respectively. Hydrophobic interactions are also formed between aconitine and residues Phe253 
and Trp85 in beta-1 adrenergic receptor. 
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3.4 EXPERIMENTAL VALIDATION 
3.4.1 The Effects of Drugs on Heart Failure 
3.4.1.1 Effect of SND on Normal Heart Function Measured by Hemodynamic Index 
Table 3. Effect of SND on Normal Rats Measured by Hemodynamic Index 
Before Drug Administration After SND administration 
SBP mmHg 101.9±23.0 119.8±20.2** 
DBP mmHg 84.7±18.0 102.1±16.7** 
MBP mmHg 93.8±20.4 111.6±18.4** 
HR bpm 387±21  399±9* 
LVSP mmHg 137.2±9.2 154.4±12.2 
LVEDP mmHg 9.1±5.6 9.5±5.7 
+dp/dt max mmHg/s 4952.1±596.0 5902.8±511.6* 
Table 4. Effect of Aconitine on Normal Rats Measured by Hemodynamic Index 
Before Drug Administration 
After AC (10µg/kg) 
Administration 
SBP mmHg 96.7±11.4 112.7±10.5** 
DBP mmHg 67.5±10.4 82.7±10.4** 
MBP mmHg 80.1±11.1 94.9±10.0** 
HR bpm 388±47 412±57* 
LVSP mmHg 108.6±6.6 121.5±6.2* 
LVEDP mmHg 8.9±3.0 7.6±3.0* 
+dp/dt max mmHg/s 3473.1±367.4 4078.1±402.0* 
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SBP, systolic blood pressure; DBP, diastolic blood pressure; medium blood pressure; HR, 
heart rate; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic 
pressure; +dp/dtmax , the maximum rate of change of ventricular systolic Values; AC, aconitine. 
Data shows as mean ± SD, n=5, *p<0.05，** p<0.01 
We assessed the effect of SND and aconitine on normal heart function on rats using the 
hemodynamic parameters as measurements. As shown in Table 3, treatment with SND resulted 
in a significant improvement in normal heart function, as reflected by an increase of left 
ventricular systolic (LVSP, from 137.2±9.2 to 154.4±12.2) and end-diastolic pressures (LVEDP, 
from 9.1±5.6 to 9.5±5.7) and heart rate (HR, from 387±21 to 399±9), systolic blood pressure 
(SBP, from 101.9±23.0 to 119.8±20.2), diastolic blood pressure (DBP, from 84.7±18.0 to 
102.1±16.7), maximal rate of pressure development (+dp/dt, from 4952.1±596.0 to 
5902.8±511.6). We further evaluated the effect of aconitine (as an constituents we predicted to 
be representative and active in aconitum) on normal heart function on rats. As Table 3 shown, we 
observed almost the same cardio inotropic effect on rats treated with aconitine as on rats treated 
with SND, with an dramatic increase in the hemodynamic indexes (LVSP, from 108.6±6.6 to 
121.5±6.2; SBP, from 96.7±11.4 to 112.7±10.5; DBP, from 67.5±10.4 to 82.7±10.4; MBP, 
80.1±11.1 to 94.9±10.0; HR, from 388±47 to 412±57; +dp/dt, from 3473.1±367.4 to 
4078.1±402.0), merely with trifling discrepancy in HR (from 388±47 to 412±57). Our results 
match results the previous studies focus on SND, and validated that aconitine have similar effect 
on heart function with SND, showing the rationality of choosing aconitine as the constituents to 
represent AC. 
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3.4.1.2 Echocardiographic Assessment 
We examined the systolic function in sham operated and HF rats compared to HF rats 
treated with SND, using echocardiography. As shown in Figure 21, two-dimensional M-mode 
echocardiography in rat models with sham operation, HF and drugs-treated groups showing 
evidence of cardiac failure with chamber dilation in HF rat. Drug administration prevented the 
development of chamber dilatation in HF rats. This result shown that the HF model was 
successfully established, and treatment with SND in HF rats resulted in a significant 
improvement in left ventricle (LV) systolic function. 
Figure 21. Echocardiography in HF Rats with Sham Operation, HF, and Drug 
The summary data for echocardiographic measurements for HF models was shown in 
Table 5 and Table 6, depicting a dramatic decline in ejection fraction, fractional shortening, and 
stroke volume in HF models compared with sham operation group.  However, these reductions 
were significant improved in HF rats treated with SND at 21 days of follow-up. Moreover, the 
notably raised left ventricular volume and diameters in systole and diastole detected in HF 
models were also compromised by the treatment with SND. The results indicated that the HF 
model was successfully established and SND treatment had therapeutic effects on the established 
HF models.  
A. SHAM B. HF C. SND
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Table 5. Effect of SND on HF Model Measured by Echocardiographic Data 
SHAM HF SND+HF 
LVIDs (mm) 2.68±0.90 8.52±0.51* 7.82±0.59 
LVIDd (mm) 6.45±0.67 9.86±0.55* 9.54±0.70 
LVESV (mL) 30.38±20.61 397.60±52.93* 329.50±57.91 
LVEDV (mL) 214.36±50.25 549.72±66.78* 511.90±87.93 
EF (%) 86.98±6.89 27.73±1.64* 35.58±4.27▲ 
FS (%) 59.23±10.29 13.68±0.86* 18.03±2.47▲ 
*p<0.05 comparing HF and sham animals,
▲p<0.05 comparing drug treatment and HF animals. 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVIDd, left ventricular internal diameter in diastole; LVIDs, left ventricular internal diameter in 
systole; EF, ejection fraction; FS, fractional shortening; SV, stroke volume; HR, heart rate; HF, 
heart failure; MI, myocardial infarction.  
Sham, sham operations, Sham surgery is a faked surgical intervention that omits the step thought 
to be therapeutically necessary. It is an important scientific control that isolates the specific 
effects of the treatment as opposed to the incidental effects caused by anesthesia, the incisional 
trauma, pre- and post-operative care. 
Data are shown as mean ± S.D. 
3.4.1.3 Effects of Drugs on MASSON 
The HE-stained images of left ventricular tissue were shown in Figure 22, where 
cardiomyocytes in the sham group were orderly arranged, and the nuclei were lightly stained. 
Thickening and lengthening of myocardial fibers could be observed in model group. 
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Cardiomyocyte hypertrophy and cellular degeneration significantly improved in the different 
drug groups in contrast with those in the model group. 
Figure 22. Effects of Drugs on MASSON and HE Stained Results in HF Rats 
For HE stain, Hematoxylin and eosin stain is one of the principal stains in histology. 
Hematoxylin is a dark blue or violet stain that is basic and positive, binding to basophilic 
substances, coloring DNA/RNA (nuclei of cells), keratohyalin granules, and calcified material. 
Eosin is a red or pink stain that is acidic and negative, which binds to acidophilic substances, 
such as proteins, and colors them in various shades of red, pink and orange. For Masson's 
trichrome staining, a three-color staining protocol used in histology: red color represents keratin 
and muscle fibers, blue or green color represents collagen and bone, light red or pink stands for 
cytoplasm, and dark brown to black stands for cell nuclei.  
3.4.2 The Effect of Liquiritin on Arrhythmia Induced by Aconitine 
The typical electrocardiograms of normal ECG (A), premature beats (B), ventricular 
tachycardia (C) and cardiac arrest (D) are shown in Figure 23. Table 7 (Figure 25) shows the 
time of the occurrence of premature beats, ventricular tachycardia and cardiac arrest, they are 
6.60±1.88 min, 7.82±2.42 min, and 14.33±2.60 min respectively in group A, and 8.20±2.06 min, 
11.36±2.46 min, and 25.28±3.51 min in group B, indicating that the use of 4 mg/kg Liquiritin 
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could significantly delay the time for occurrence of premature beats, ventricular tachycardia and 
cardiac arrest induced by aconitine (10µg/ml in a speed of 0.1ml/min, i.v.). Calculated with the 
time and the concentration of the aconitine, the dosages of aconitine, under which could lead to 
premature beats, ventricular tachycardia and cardiac arrest are shown in Table 7 (Figure 25), 
21.30±4.72 µg/kg, 25.19±6.26µg/kg, and 46.72±6.60µg/kg in group A, and 31.41±7.85µg/kg, 
43.42±8.90µg/kg, and 97.72±18.96µg/kg in group B. The dosages of aconitine which causes 
premature beats, ventricular tachycardias and cardiac arrest interventions with Liquiritin are 
nearly two times than that in group A. It is supposed that the Liquiritin could probably ease the 
arrhythmia caused by aconitine, and thus reduce the toxicity of aconitine. (Table 8 and Figure 
24) 
 
Figure 23. Typical ECG of Normal condition, Premature Beats, Ventricular Tachycardias, and 
Cardiac Arrest 
 
Table 6. The Time of Premature Beats, Ventricular Tachycardia, and Cardiac Arrest 
  Aconitine Aconitine+ 4 mg/kg Liquiritin 
Premature Beats  6.60±1.88 Min 8.20±2.06 Min 
Ventricular Tachycardia  7.82±2.42 Min 11.36±2.46*Min 
Cardiac Arrest  14.33±2.60 Min 25.28±3.51*Min 
*p <0.05 vs group aconitine 
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Table 7. The Dosage of Aconitine under occurrence of Premature Beats, Ventricular 
Tachycardia, and Cardiac Arrest 
  Aconitine Aconitine+ 4 mg/kg Liquiritin 
Premature Beats  21.30±4.72 µg/kg 31.41±7.85* µg/kg 
Ventricular Tachycardia  25.19±6.26 µg/kg 43.42±8.90* µg/kg 
Cardiac Arrest  46.72±6.60 µg/kg 97.72±18.96** µg/kg 
* p <0.05, ** p <0.01 vs group aconitine 
 
 
Figure 24. The dosage of aconitine under the occurrence of premature beats, ventricular 
tachycardia and cardiac arrest  
 
Figure 25. The occurrence time of premature beats, ventricular tachycardia and cardiac 
arrest 
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3.4.3 The Effect of 6-Gingerol And Aconitine on Heart Function  
 
We assessed the effect of aconitine combined with 6-gingerol on heart function compared with 
aconitine along by hemodynamic measurements. As shown in Table 9 treatment with aconitine 
resulted in a significant improvement in heart function, as reflected in an increase of left 
ventricular systolic (LVSP) and end-diastolic pressures (LVEDP) and heart rate (HR), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), maximal rate of pressure development 
(+dp/dt). Combined with 6-gingerol (aconitine: 6-gingerol= 1:7), the inotropic cardiac effect of 
aconitine was further enhanced with significant raise in blood pressure (LVSP, from 121.5±6.2 
to 140.0±12.4; LVEDP, from 7.6±3.0 to 9.3±3.3; SBP, from 112.7±10.5 to 113.6±12.8; DBP, 
from 82.7±10.4 to 92.2±11.8; MBP, 94.9±10.0 to 103.0±11.4) and maximal rate of pressure 
development (+dp/dt, from 4078.1±402.0 to 6080.2±891.2). Interestingly, the increase in the 
heart rate caused by aconitine was attenuated by the addition of 6-gingerol, from 412±57 to 
386±24. 
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Table 8. Summary of Hemodynamic Data with Combined Use of Aconitine and 6-gingerol  
  
AC 10ug/kg AC 10ug/kg+6-gingerol 70ug/kg 
Before 
administration 
After 
administration 
Before 
administration 
After administration 
SBP (mmHg) 96.7±11.4 112.7±10.5** 97.1±9.4 113.6±12.8** 
DBP (mmHg) 67.5±10.4 82.7±10.4** 74.3±6.7 92.2±11.8** 
MBP (mmHg) 80.1±11.1 94.9±10.0** 85.7±7.2 103.0±11.4** 
HR  (bpm) 388±47 412±57* 365±35 386±24 
LVSP (bpm) 108.6±6.6 121.5±6.2* 123.9±13.4 140.0±12.4* 
LVEDP (bpm) 8.9±3.0 7.6±3.0* 6.8±6.2 9.3±3.3 
+dp/dtmax(mmHg/s) 3473.1±367.4 4078.1±402.0* 5274.4±661.8 6080.2±891.2* 
 
  
 AC 5ug/kg AC 5ug/kg+6-gingerol 35ug/kg 
Before 
administration 
After 
administration 
Before 
administration 
After 
administration 
SBP (mmHg) 101.8±16.2 109.2±18.0 100.4±10.0 115.9±22.7** 
DBP (mmHg) 76.5±23.0 84.2±22.1 73.1±9.2 86.9±12.0* 
MBP (mmHg) 87.1±20.6 94.9±20.3 86.5±9.6 100.9±15.8* 
HR  (bpm) 395±43 405±16 358±46 368±30 
LVSP (bpm) 115.3±9.6 121.6±8.9 119.1±16.3 135.7±18.0 
LVEDP (bpm) 7.5±1.1 7.4±1.0 3.8±6.2 7.3±4.2 
+dp/dtmax 
(mmHg/s) 
3879.7±515.0 4156.7±301.5 4948.3±592.6 5529.2±535.0** 
SBP, systolic blood pressure; DBP, diastolic blood pressure; medium blood pressure; HR, 
heart rate; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic 
pressure; +dp/dtmax , the maximum rate of change of ventricular systolic Values; AC, aconitine. 
Data shows as mean ± SD, n=3, *p<0.05，** p<0.01 
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3.4.4 The Validation of Predicted Targets with Constituents in SND 
 
3.4.4.1 The Validation of Aconitine to Beta-1 Adrenergic Receptor  
By administrating simultaneously with propranolol, we can validate whether the 
propranolol, a long-known beta-1 adrenergic antagonist, can block the cardiac inotropic effect 
caused by administration of aconitine. As shown in Figure 26, the increase in HR and ±dp/dtmax 
due to the administration of aconitine was blocked by propranolol, indicating the possibility that 
aconitine may have its inotropic cardiac effect via acting on beta-1 adrenergic receptor. 
Moreover, the change rates in HR and ±dp/dtmax after administration were almost the same for 
the two groups: propranolol and aconitine, propranolol and saline, but the change rates for 
another group with treatment of aconitine alone is significantly larger than the two groups. This 
result indicated that propranolol could block most of aconitine’s effect on heart function, 
indicating the possibility that aconitine may act on beta-1 adrenergic receptor to have its 
therapeutic function. 
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Figure 26. The Change Rate of HR and dp/dt after treatment of Propranolol and Aconitine  
The change rate of heart rate (A) and the maximum rate of change of ventricular systolic values 
dp/dt max (B) after administration of aconitine (AC) and propranolol (PRO), aconitine and 
normal saline (NS), and propranolol and NS. 
 
 
 
 
  
A. 
B. 
min 
min 
Change rate 
Change rate 
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4.0 DISCUSSION 
 
4.1 SYNERGISTIC EFFECT OF THREE INGREDIENTS IN SND 
 
 
 
Figure 27. The predictions of synergistic effect mechanism for SND 
Multiple constituents in Sini Decoction (SND) act on multiple targets in the context of several 
physiological systems to achieve synergistic effects. The large circles with figures inside show 
the three herbs in SND. The gray nodes represent our predicted therapeutic targets. These targets 
are linked with the herbs and related pathways by gray lines. Green rectangles represent the 
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pathways that the predicted therapeutic targets are involved in. Blue rectangles represent the 
therapeutic effects according to different targets, pathways, and herbs. Red rectangles show the 
synergistic effects of the combined use of three herbs in SND. The therapeutic effects are linked 
with their corresponding targets and synergistic effects by lines. 
 
 
SND, originally recorded in Treaties of Febrile diseases, has a long history of use as a 
treatment for cardiovascular diseases (CVDs). People applied SND as a life-saving drug to treat 
patients with heart failure, myocardial infarction, shock, and other serious diseases [58]. 
According to the previous literature, SND can ameliorate lipid profiles, improve microcirculation 
[59], and increase blood pressure to help blood reflux to the heart and to help improve 
circulation. This process keeps people warm and can help to treat Yang deficiency. SND can also 
restore the function of heart, thus pulling the blood to the system circulation more powerfully 
with a higher frequency [60, 61]. Thus SND is useful to treat patients with diseases caused by 
weak circulation, such as rheumatism, general debility, cardiac weakness, weak circulation, and 
decreased kidney function [62]. 
In the SND formula, aconite (emperor) plays a dominating role in treating the primary 
causes of disease [63, 64]. Herbalists believed that aconite could resurrect the dead. Previous 
studies indicated that the hydrophilic parts of AC showed a strong cardio tonic effect in the heart 
of frogs, toads, and warm-blooded animals, either in their normal or diseased condition [65]. 
Some research claimed that aconite and its extract could protect the myocardial cells of animal 
models and patients with heart failure, myocardial infarction, cardiac hypertrophy, and other 
CVDs [66]. However, aconite is well known as a poisonous herb whose improper use can cause 
human respiratory paralysis, cardiac arrest, and even death [67, 68]. 
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Ginger (minister) might enhance the effect of aconite and treat accompanying symptoms 
of CVDs [69]. Ginger extract can ease pain [70], prevent inflammation [71, 72], temporarily 
elevate blood pressure [73], fight against hypercholesterolemia [74], and prolong thrombus 
formation time in rats [60, 75].  
Licorice as “zuoshi” (adjuvant-courier) in SND formulation is used to reduce the toxicity 
of aconite in fighting arrhythmia and inducing glucuronide-like detoxification [76]. Licorice also 
has other functions that can help to alleviate CVD symptoms, such as antibacterial [77], antiviral, 
anti-inflammatory [77], and hypertensive effects [78]. Licorice is used as a unique “guide drug” 
in many herbal formulations in TCM. It works through altering the enzyme activity of P450 and 
modulating of the drug transporter protein such as P-glycoprotein [79].  
By using the systems polypharmacology approach to further investigate the target 
proteins connected with multiple compounds, we found most of these shared targets belong to a 
few physiological systems: the renin-angiotensin-aldosterone system (yellow square), the 
coagulation pathway (purple square), lipid metabolism (blue square), and the auto nervous 
system (rubber red square). These shared targets contribute to the synergistic effect of SND, 
revealing the underlying mechanism of SND formulation. 
 
4.1.1 Major Constituents from Three Herbs Acting Synergistically on RAAS 
 
Multiple constituents in SND are predicted to act on four targets in RAAS (renin-angiotensin-
aldosterone system): ACE, AGTR, AGT, and renin. As shown in Figure 28A, renin is an 
enzyme that breaks down angiotensinogen (AGT) into angiotensin I. Angiotensin I is further 
cleaved in the lung by ACE into angiotensin II. Angiotensin II, the most potent compound in this 
system, can act on AGTR to attain two functions: (1) causing vasoconstriction, which increases 
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the peripheral vascular resistance that the heart needs to overcome, thus enhancing cardiac output 
and blood pressure; and (2) inducing the release of aldosterone, which stimulates the epithelial 
cells in kidneys distal tubule and collecting ducts to increase re-absorption of sodium and water, 
and increase excretion of potassium, leading to an increased blood volume and pressure  [80, 81]. 
Moreover, the inhibitors for RAAS are widely used to treat cardiovascular diseases, like 
hypertension and heart failure [82, 83]. As shown in Figure 28A, GU, ZO, and AC exert 
synergistic efficacy by increasing the plasma concentration of angiotensin II via three targets 
(ACE, AGT, and renin) or by achieving the angiotensin II effect by directly interacting with 
AGTR, thus boosting blood pressure, increasing cardiac output, and improving circulation. GU 
[84-86] and ZO [87-90] have already been demonstrated to act on RAAS, whereas the influence 
of AC on RAAS requires further investigation. 
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Figure 28. Multiple Targets from the RAS System and Coagulation Pathway  
(A) The role of the four targets (ACE, AGT, AGTR, and REN) in the RAS physiological system 
(the figure was adapted from the website: http://bookcoverimgs.com/renin-angiotensin-system/). 
(B) The roles of multiple potential targets in the coagulation pathway (the figure was adapted 
from [91]). 
A. 
B. 
  69 
4.1.2 Multiple Components Interact with Multiple Targets in the Coagulation System  
Multiple constituents in SND are predicted to interact with five targets in the coagulation 
system: FII, FX (coagulation factor X), FVII (coagulation factor FVII), PAF (platelet activation 
factor), and antithrombin III (ATIII). As shown in Figure 28B, the coagulation system includes 
three parts: fibrinolysis, platelet aggregation, and coagulation cascade; most of our potential 
targets are involved in the coagulation cascade. The intrinsic pathway and the extrinsic pathway, 
both found in the blood coagulation cascade, lead to the activation of FX, which converts 
prothrombin (FIII) to thrombin, resulting in fibrin formation [92]. The pathways are a series of 
reactions, in which inactive pro-enzymes and their cofactors are turned into active forms that can 
catalyze the next reaction in the cascade, amplifying the process and culminating in the 
formation of thrombin [93]. Most coagulation factors are serine proteases that can be converted 
to their active forms to act on a downstream reaction; but FVIII and FV are glycoproteins 
cofactors. The intrinsic pathway is initiated by the activation of FXII, followed by the sequential 
activation of FXI and FIX, leading to the activation of FX [94]. The extrinsic pathway is initiated 
by the formation of the complex TF-FVII; TF-FVIIa activates FX; FXa convert FIII 
(prothrombin) to thrombin, which not only converts fibrinogen to fibrin, but also activates 
platelet, FVIII, FV, and FXIII, which forms covalent bonds that crosslink the fibrin polymers, 
stabilizing fibrin cloting [92].  
Herbs in SND interrelate with FII, FX, and FVII. Each factor plays a role in the 
coagulation cascade, thus allowing SND to inhibit the process of blood coagulation and reduce 
thrombus and blood clots through blocking these coagulation factors. In addition, some target 
proteins, hit by compounds of SND, are involved in the anticoagulation processes (ATIII) and 
platelet aggregation (PAF). Antithrombin III (also termed as ATIII) is a serine protease inhibitor 
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that is constantly active to degrade the serine proteases: thrombin, FIXa, FXa, FXIa, and FXIIa. 
Fibrinolysis is the process in which the tissue plasminogen activator (t-PA) and urokinase (uPA) 
trigger the transformation from plasminogen (PLG) to active plasmin, which breaks down fibrin, 
in order to maintain the size of clots and prevent thrombosis [93]. SND might have the potential 
of addressing multiple targets to keep hemostatic balance for smooth blood circulation, therefore 
conquering and preventing many complex cardiovascular diseases. 
 
4.1.3 Herbs in SND Acting Synergistically to Improve the Lipid Profile 
Multiple compounds from three herbs in SND target HMGCR, the rate-limiting enzyme 
in the process of synthesis of cholesterol. There are mainly four sources of cholesterol in human 
bodies: dietary uptake, retake from recycling bile acid, biosynthesis in the liver, and uptake from 
circulation by low-density lipoprotein (LDL) receptors on the liver [95]. When HMGCR is 
inhibited, less cholesterol will be synthesized. The liver can take in more LDL, leaving less LDL 
in the plasma, thus resulting in lower LDL and cholesterol plasma concentration in the body.  
Multiple constituents in SND can also interact with peroxisome proliferator-activated 
receptor gamma (PPARG), to regulate fatty acid storage and glucose metabolism. PPARG is a 
regulator of adipocyte differentiation, and it stimulates lipid uptake and adipogenesis [96]. 
PPARG knockout mice cannot generate adipose tissue even when fed with a high-fat diet [97]. 
PPARG has been emphasized in the etiology of numerous diseases including obesity, diabetes, 
atherosclerosis, and cancer. PPARG decreases the inflammatory response of many 
cardiovascular cells [98], and increases synthesis and release of paraoxonase 1 from the liver by 
gene regulation, thus reducing atherosclerosis [99]. In addition, known agonists of PPARG have 
been used in the treatment of hyperglycemia [100] and hyperlipidaemia [101]. Many insulin-
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sensitizing drugs used in the treatment of diabetes, such as the thiazolidinediones, target PPARG 
as their molecular mechanisms to lower serum glucose without enhancing secretion of pancreatic 
insulin [102, 103]. According to our predictions, PPARG might interact with glycyrrhetinic acid, 
one of the major constituents in liquorice, thus reducing the inflammatory response of many 
cardiovascular cells, regulating fatty acid storage to improve plasma lipid profile, and controling 
glucose metabolism to reduce the blood glucose level. This prediction is consistent with the 
experimental data, which reported that glycyrrhetinic acid did shown activity binding with 
PPARG [104]. 
The constituents in SND can act on both PPARG and HMGCR to improve serum lipid 
profile. An improved serum lipid profile will enhance circulation and provide a more efficient 
vessel condition to prevent CVDs, such as atherosclerosis, shock, and stroke [105]. Recent 
research have also shown that aconite extract increased the hepatic LDL receptor, decreased 
HMGCR expression, and lowered cholesterol levels in rats [106]. Rats treated with ginger 
extract displayed a significant dose-dependent reduction in the serum cholesterol level, LDL-C, 
and serum triglyceride (TC) level, demonstrating a more efficient anti-hypercholesterolemic 
effect of ginger at a higher dose than Atorvastatin [107]. Glycyrrhizin (27) is also able to fight 
against hyperglycemia and hyperlipidemia [108]. Clinical studies demonstrated that licorice has 
desirable effects on preventing inflammatory processes in blood vessels, decreasing LDL, 
reducing plasma lipid levels, and lowering systolic blood pressure [109]. The results of these 
studies all match our predictions that SND can improve lipid profile. 
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4.1.4 Liquorice can Alleviate Arrhythmia Caused by Aconitum 
 
Aconites from Radix Aconiti were proven to have cardiac toxicity, like causing arrhythmia [110]. 
According to the prescription database analysis platform of Radix Aconiti, 29.52% of 3188 
prescriptions that contains aconite, are combined with liquorice to reduce the toxicity of aconite 
[111]. GU contains isoliquiritigenin (31), liquiritin (28), licoricidin (34), glycyamarin (30), 
isoliquiritin (37), and glycyrol (33), which are predicted to interact with potassium channels, 
sodium ion channels and beta-1 adrenergic receptor respectively. These targets are coincident to 
be some of the drug targets for the treatment of arrhythmia. The following drugs are all in the 
market or clinical trials for the treatment of arrhythmia: Procainamide, Lidocaine, Pyrazole 
amine, Phenytoin sodium, and Propafenone acting as sodium channel blockers; Amiodarone, 
Bromine, Sotalol, Benzyl ammonium, and Ibutilide blocking potassium current of myocardial 
cells and extending action potential duration; and, Metoprolol, Esmolol, and Bisoprolol 
inhibiting ADRB1 [112]. Liquorice was reported to fight against arrhythmia via inhibitory 
effects on the potassium current [113] and sodium channel [114]. Some compounds in liquorice 
can have an antitoxin effect similar to glucocorticoid (GC), to help reduce the toxicity of 
aconitum [115]. The anti-inflammatory and anti-shock effect of Glucocorticoid receptor (GCR) 
from liquorice and ginger also help to heal accompanying illness and contribute to the synergistic 
effect of SND.  
One of the major components in liquorice, glycyrrhetinic acid, is predicted to interact 
with the 11β-hydroxysteroid dehydrogenases (11β-HSDs) to mimic the effect of glucocorticoid, 
which is consistent with the literature reports [116]. As shown in Figure 29, the 11β-
hydroxysteroid dehydrogenase isozymes 1 (11β-HSD1) and 2 (11β-HSD2) are the catalysts for 
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the inter-conversion between cortisone and cortisol [116]. 11β-HSD1 converts cortisone to the 
active glucocorticoid cortisol while the 11β-HSD2 catalyzes the transformation from active 
cortisol to inactive cortisone. Inhibition of 11β-HSD2 could be used to potentiate the anti-
inflammatory effects of glucocorticoids due to a reduction in the amount of glucocorticoid. 
Aldosterone and glucocorticoids exerted a similar, concentration-dependent chronotropic action 
on cardiomyocytes, which was mediated by both the mineralocorticoid and glucocorticoid 
receptors [115]. Components in liquorice and ginger that interact with targets in RAAS 
influencing the function of aldosterone (mineralocorticoid), which might also aid to fight agnoist 
cardio toxicity of aconite [117]. 
 
 
  
Figure 29. Interconversion of Cortisone and Cortisol Catalyzed by 11β-HSD 1 and 11β-
HSD 2 
 
Liquorice is frequently used in TCM for detoxification, and previous studies reported that 
paired use of GU and AC will reduce the toxicity of aconite and are declared to be safe, which 
matches our prediction [76, 111, 118, 119].  
Among all constitutes in liquorice, liquiritin seems to be more representative as it is 
predicted to act the sodium, the voltage-gated potassium channels, and the beta-1 adrenergic 
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receptor, according to our results. Then we tested the selected active components pair of 
liquiritin and aconitine (selected active compound in aconitum) by recording the 
electrocardiograms of normal ECG, premature beats, ventricular tachycardia and cardiac arrest. 
We observed that the administration of liquiritin could alleviate the cardio toxicity of arrhythmia 
caused by aconitine in mice, shown by significantly delayed time of premature beats, ventricular 
tachycardia, and cardiac arrest, induced by aconitine. This result validated our prediction that the 
liquiritin was the active component responsible for the antiarrhythmic effect of liquorice (Figure 
23, Figure 24, Figure 25, Table 7, and Table 8). 
 
4.1.5 The Synergistic Effect of Ginger and Aconitum Pair  
We also tested the synergistic effect for the combination of our selected compounds 6-
gingerol and aconitine to evaluate whether 6-gingerol is the active component in ginger, which 
can improve the therapeutic effect of aconitum. As shown in previous reports, Ganjiang (ginger) 
−Fuzi (aconitum) pair has been used for more than 2000 years in a ratio of one to one for ginger 
and aconitum in weight. This herbal pair has dispelled internal cold and recuperates depleted 
yang activities to treat patients with Yang deficiency, which can be reflected as deadly cold 
limbs and a sunken and feeble pulse [7, 120, 121]. After being combined with ginger, the cardiac 
effect of aconitum was enhanced, reflected by the increased force of cardiac muscle systole, 
improved cardiac energy metabolism, reduced left ventricular end-diastolic pressure (LVEDP), 
improved heart compliance and altered hormone regulation [122-124]. Thus, aconitum are 
reported to have improved therapeutic effect in curing heart failure when combined use with 
ginger. In order to evaluate whether the 6-gingerol in ginger or the aconitine in aconitum is 
responsible for their therapeutic and synergistic effects in treating heart failure, we measured the 
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effect of aconitine combined with 6-gingerol, compared with aconitine along by recording the 
hemodynamic parameters, such as left ventricular systolic (LVSP) and end-diastolic pressures 
(LVEDP) and heart rate (HR), Systolic blood pressure (SBP), diastolic blood pressure (DBP), 
maximal rate of pressure development (+dp/dt). We observed increase of all the hemodynamic 
measurements on mice induced by the administration of aconitine, indicating that aconitine is at 
least one of the major components possess therapeutic activity. These increases were further 
improved by the combination with 6-gingerol, indicating the 6-gingerol is responsible for the 
synergistic effect in ginger. These results validate our prediction about active components in 
ginger and aconitum that participate in the synergistic effect of SND (Table 9). 
 
4.1.6 Compounds act on targets in autonomic nerves system (ANS)  
Beta-1 adrenergic receptor, a G-protein coupled receptor, predominantly expresses in 
cardiac tissues. ADRB1 can raise heart rate in sino atrial node (SA node), enhance contractility 
and automaticity of ventricular cardiac muscle, and elevate conduction of atrioventricular node 
(AV node), thus increasing cardiac output [125]. ADRB1 is the potential target linked to the 
largest number of components in our prediction. Higenamine, a constituent in AC, was reported 
to have a cardio tonic effect on cardiac chronotropic and inotropic actions mediated by ADBR1, 
which matches our prediction [126]. Low dose of mesaconitine was shown to stimulate beta-
adrenoceptors in hippocampus, evoking long lasting excitatory effects, to exert accompany 
function like hypertensive effect and analgesia effect [127]. Our experiments results shown the 
inotropic actions and following pressure changes induced by aconitine was 
compromised/counteracted by the pro-administration of propranolol, a well-known beta 
adrenergic antagonist, indicating the possibility that the aconitine may act on beta adrenergic 
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receptor, especially beta-1 adrenoceptor, to achieve its effect on increasing heart rate and blood 
pressure [128] (Figure 26). 
The M2 muscarinic receptors (M2AChR) are cholinergic receptors that act on 
myocardium to slow down the heart rate and lessen the cardiac output by delaying the speed of 
depolarization, reducing conduction of AV node, and decreasing contractile forces of the atrial 
cardiac muscle [129]. Multiple compounds from SND target M2AChR to regulate the heart rate 
and heart output, and to achieve cardio tonic effect against disease conditions. M3AChR 
mediates vessel constriction by regulating intracellular calcium in smooth muscles, which is also 
correlated closely to blood pressure. Liquorice and ginger [130] may act on M3AChR to exert 
precondition-mediated cardio protective efficacy against aconite-induced arrhythmia [131]. 
Acetyl cholinesterase (AChE) inhibits the metabolism of acetylcholine (ACh), resulting in the 
accumulation of ACh in the synaptic cleft, which will stimulate sympathetic nervous system for 
a long time [132]. Liquorice is demonstrated to interact with AChE, which matches our 
prediction [133]. According to previous studies, 6-gingerol [134] and glycyrrhetinic acid [135] 
have shown binding affinity with AChE, for Ki of 10.6nM and 31.2nM respectively, which is in 
consistent with our prediction. We predicted that Liquiritin can interact with ADBR2, this 
prediction has already been demonstrated by qHTS screening for beta2-adrenergic receptor with 
an IC50 of 6µM [128].  
As shown in Table 10, some of our predicted targets for the constituents have already 
been validated by other literature reports, indication the reliability of our prediction 
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Table 9. The Validated Interaction between SND Components and Predicted Targets 
Compound 
Name 
Abbervia
tion 
Target Name Assay Value Reference 
6-gingerol AChE Acetylcholinesterase  Ki 0.0106 [134] 
6-gingerol TRPV1 Transient receptor potential cation 
channel subfamily A member 1 
Efficacy 0.114 [136] 
6-gingerol LTAH4 Leukotriene A4 hydrolase  Efficacy 0.114 [137] 
aconitine CHRNA7  Neuronal acetylcholine receptor 
protein alpha-7 subunit 
Ki 2.12nM [138, 139] 
glycyrrhetinic 
acid  
PPARG Peroxisome proliferator-activated 
receptor gamma 
Activity Active [104] 
glycyrrhetinic 
acid  
HSD-11β 11-beta-hydroxysteroid 
dehydrogenase 2  
IC50 1nM [120] 
glycyrrhetinic 
acid  
AChE Acetylcholinesterase  INH 0.0312 [135] 
liquiritin ADRB2  Beta-2 adrenergic receptor IC50 6.5131uM 
glycyrrhetinic 
acid  
AKR1B10 Aldo-keto reductase family 1 
member B10 
IC50 =4.9uM [140] 
glycyrrhetinic 
acid  
POLL DNA polymerase kappa  Active Active [141] 
Aconitine  Tetrodotoxin-sensitive, voltage-
dependent sodium channels 
Active Active [128] 
Glycyrin GCR Glucocorticoids receptor IC50 2.6uM [142] 
Higenamine ADRB1 Beta-1 adrenergic receptor Active Activey55 [126] 
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5.0 CONCLUSION 
To summarize, we initially constructed a comprehensive database for CVDs research. We 
then applied this database to predict the active constituents linked to potential targets for SND 
through the construction of the biological target-compound network at the molecular level. The 
results showed that 31 constituents interacting with 33 targets, which have a significant 
relationship with pathological processes of cardiovascular diseases (CVDs), such as the 
thrombosis process, lipid profile (HMGCR, PPARG), and blood pressure regulation (RAAS, 
AGTR, ADBR, and M2AChR). Also, multiple compounds in this formula could interact with the 
same targets simultaneously, which offers a good explanation for the synergistic mechanisms of 
TCM. Based on the network analysis, we further explored the underlying mechanism of the SND 
formula with the “Jun-Chen-Zuo-Shi” principle.  
The results revealed that aconite (empire) plays an important role in RAAS, HMGCR, 
ANS, and the coagulation system to cure symptoms of CVDs.  Multiple constituents in aconitum 
might interact with multiple targets, such as renin, ADRB1, ACE, HMGCR, ADRB1, and FII, to 
treat the primary cause of the disease. On the other hand, ginger and liquorice reacted with 
multiple targets, some of which were also targeted by aconite. Some other targets may not share 
by different herbs, but still in the same pharmacological process and will produce similar actions 
to improve the efficacy of aconite. Interestingly, ginger (Chen) was predicted to not only interact 
with many target proteins (PPARG, HMGCR) in the same physiological system as the other two 
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herbs to strengthen the effect of aconitum, and but also act on other targets (TRPV1, LTAH4, 
and COX2) relevant to the immune and inflammatory processes to remedy concomitant 
complications with CVDs. Liquorice (Zuo) can alleviate arrhythmia caused by aconite via  
reaction with potassium ion channels, sodium ion channels, ADBR1 and HSD-11β, thus 
reducing toxicity of aconite.  
These predicted results are in agreement with the rationality of the formula, involving the 
mutual reinforcement of therapeutic efficacy and reduction of adverse effects. In addition, some 
of our predicted interactions (like AChE-6-gingerol, glycyrrhetinic acid-PPARG) are also in 
accordance with the previous literature (as shown in Figure 10). We did further experimental 
validation on normal rats and HF and MI rat models to validate the function of the constituents 
(liquiritin, 6-gingerol, and aconitine), which we selected for each herb form SND and predicted 
would have therapeutic and synergistic effects,. We found that aconitine is effective and 
powerful in improving heart function on HF, MI and normal rats; liquiritin can reduce the 
arrhythmia induced by aconitine; and 6-gingerol can improve the effect of aconitine on heart 
function. Finally, we selected ADBR1 as an example and partially validated our prediction that 
aconitine act on ADBR1. 
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6.0 FUTURE PROSPECTIVE 
 
To further evaluate the molecular mechanism of the synergistic effects in SND and to 
make sure our predictions were correct, we will need more specific experimental validation. We 
plan to perform some protein binding assays between our selected representative compounds 
(liquiritin, aconitine, and 6-gingerol) and our predicted target proteins (PPARG, HMGCR, and 
ACE). We selected the protein-binding assay of these target proteins based on the following 
reasons: first, these target proteins are well-known therapeutic targets for the treatment of CVDs 
in the clinic. Moreover, the effects induced by the activations or inhibitions of these targets are 
identical with the therapeutic effects of SND and effects of individual herbs in SND. 
Furthermore, the purified proteins for these targets used in the binding assays are commercially 
available, and the experimental protocols are easily found with the well-established binding 
assays for these proteins. Lastly, the protein-binding assay is simple and specific to validate our 
prediction about target-drug interaction. If the constituents were demonstrated to interact with 
the proteins, we could do more cell-based assays or in vivo animal studies. 
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APPENDIX. ABBREVIATION 
 
 
5HT Serotonergic synapse 
+dp/dtmax  The maximum rate of change of ventricular systolic Values 
AC Aconitine 
ACE Angiotensin Converting Enzyme 
AChE Acetyl cholinesterase 
AD Alzheimer's disease 
ADR Adrenergic signaling in cardiomyocytes 
ADRA1 Alpha-1 adrenergic receptor 
ADRA2 Alpha-2 adrenergic receptor 
ADRB1 Beta-1 adrenergic receptor 
ADRB2 Beta-2 adrenergic receptor 
ADRB3 Beta-3 adrenergic receptor 
AGT Angiotensinogen 
AGTR Angiotensin II receptor  
AKR1B10 Aldo-keto reductase family 1 member B10 
AMPK AMP-activated protein kinase signaling pathway 
ANPR Atrial natriuretic peptide receptor A 
ANS Autonomic nervous system 
APN Aminopeptidase N 
ARVC Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
ATIII Antithrombin-III 
CACN Voltage-dependent L-type calcium channel  
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CAMP cAMP signaling pathway 
CHD Coronary heart disease 
CHO Cholinergic synapse 
CHRNA7 Neuronal acetylcholine receptor protein alpha-7 subunit 
COX-2 Prostaglandin G/H synthase 2 
CR Circadian rhythm 
CVD Cardiovascular diseases 
DBP Diastolic blood pressure 
DILATED CM Dilated cardiomyopathy 
EDNRA Endothelin-1 receptor 
EF Ejection fraction 
FII Coagulation Factor II 
FIII Coagulation factor III (tissue factor) 
FS Fractional shortening 
FV Coagulation Factor V 
FVII Coagulation factor VII 
FVIIa Coagulation factor VIIa 
FVIII Coagulation factor VIII 
FX Coagulation factor IX 
FXa Coagulation factor Xa 
FXI Coagulation factor XI 
FXIII Coagulation factor XIII 
GCR Glucocorticoid receptor 
GU Glycyrrhiza Uralensis 
HCM Hypertrophic cardiomyopathy (HCM) 
HF Heart failure 
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
HR Heart rate 
HRH1 Histamine H1 receptor 
HSD-11β 11-beta-hydroxysteroid dehydrogenase 2 
HTR Serotonin receptor 
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INSULIN Insulin signaling pathway 
KCN Potassium channel  
KvCN Potassium voltage-gated channel subfamily D member 3 
LDL Low density lipid protein 
LTAH4 Leukotriene A4 hydrolase 
LV Left ventricle  
LVEDP Left ventricular end-diastolic pressure 
LVEDV Left ventricular end-diastolic volume 
LVESV Left ventricular end-systolic volume 
LVIDd Left ventricular internal diameter in diastole 
LVIDs Left ventricular internal diameter in systole 
LVSP Left ventricular systolic pressure 
M2AChR M2 muscarinic acetylcholine receptor 
M3AChR M3 muscarinic acetylcholine receptor 
MBP Medium blood pressure 
MCR Mineralocorticoid receptor 
MI Myocardial infarction 
MM Multiple myeloma 
NS Normal saline 
PAF Platelet activating factor 
PDE3 cGMP-inhibited 3',5'-cyclic phosphodiesterase 
PI3K-AKT PI3K-Akt signaling pathway 
PLATELET Platelet activation 
PLG Plasminogen 
PN3 Sodium channel protein type 10 subunit alpha 
POLL DNA polymerase kappa 
PPAR Peroxisome proliferator-activated receptor signaling pathway 
PPARG Peroxisome proliferator-activated receptor gamma 
PRO Protein digestion and absorption 
RAAS/RAS Renin-anfiotensin-aldosterone system 
REN Renin 
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SBP Systolic blood pressure 
SCN Sodium 
SND Sini Decoction 
SV Stroke volume 
TC Serum triglyceride  
TCM Traditional Chinese medicine 
THR Thyroid hormone signaling pathway 
TNF-alpha Tumor necrosis factor alpha 
TRP Inflammatory mediator regulation of TRP channels 
TRPV1 
Transient receptor potential cation channel subfamily A 
member 1 
TTSCN tetrodotoxin-sensitive, voltage-dependent sodium channels 
uPA Urokinase-type plasminogen activator 
VEGFR Vascular endothelial growth factor receptor 
vWF Von Willebrand factor 
ZO Zingiber Officinale  
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